Self-assembling and self-adjuvanting polymer-peptide conjugates as therapeutic vaccines against cervical cancer by Liu, Tzu-Yu
	  
	  
	  
	  
Self-assembling and self-adjuvanting polymer-peptide conjugates as 
therapeutic vaccines against cervical cancer 
 
 
Tzu-Yu Liu 
 
B. Pharm, M. Sc. 
 
 
 
 
 
 
 
 
 
A thesis submitted for the degree of Doctor of Philosophy at 
The University of Queensland in 2014 
School of Chemistry and Molecular Biosciences 
 
 
 
	   ii	  
Abstract 
 
Cervical cancer is the second most common cancer in women worldwide, with approximately 500, 
000 new cases and 250,000 deaths reported annually. Human papillomavirus (HPV) is responsible 
for nearly all cases of cervical cancer with HPV type 16 (HPV-16) infection causing the majority of 
HPV-related cancers. While prophylactic HPV vaccines have been already developed and 
commercialized, they only protect the host against viral infection but have no therapeutic effect 
against established HPV infection. However, a large proportion of the global population is already 
infected and therefore, cannot be treated with prophylactic vaccination. Thus, there is strong 
demand for development of therapeutic vaccines to eradicate HPV and control cervical cancer 
mortality. Therapeutic HPV vaccine candidates are usually designed to elicit cytotoxic T cell 
responses by targeting HPV E7 and/or E6 oncoproteins as they are responsible for tumorigenesis 
and maintenance of the tumor growth. 
 
Peptide-based vaccines use only minimal non-oncogenic epitopes, necessary to stimulate an 
antigen-specific immune response. Synthetic peptide-based subunit vaccines are potentially 
excellent candidates for rational vaccine development because they are naturally non-infectious, 
completely defined, relatively easy to produce, and are generally considered to be safe. However, 
their low immunogenicity must be overcome first. All reported peptide-based therapeutic HPV 
vaccine candidates have been formulated with an adjuvant (immunostimulant) to produce the 
desired immune response. These adjuvants are often toxic or their efficacy is low. To date, only a 
few adjuvants have been approved for human use. Therefore, the discovery and development of 
novel adjuvants or self-adjuvanting delivery systems without adverse effects are in high demand to 
overcome obstacles in the field of peptide-based cancer immunotherapy.  
 
The aim of this thesis was to develop a novel peptide-based therapeutic vaccine strategy based on 
polymer conjugated to synthetic peptide epitopes derived from HPV-16 E7 oncoprotein. The 
conjugates were expected to form particles from a self-assembling process. The self-adjuvanting 
properties of self-assembled particles would remove the use of a toxic adjuvant for vaccine 
formulation. A polyacrylate polymer was selected as the most promising antigen carrier because it 
had little or no toxicity and the self-assembling and self-adjuvanting ability of polyacrylate 
amphiphilic dendrimers inducing humoral immunity has been reported. The focus of this research 
project was to rationally design and to develop an effective and safe self-adjuvanting delivery 
system for peptide-based therapeutic vaccines, which induced cellular immunity.  
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The choice of appropriate HPV epitopes is crucial for rational design of therapeutic vaccines. 
Therefore, the well-known 8Q epitope (QAEPDRAHYNIVTFCCKCD; E744-62) containing a 
cytotoxic T lymphocyte (CTL, CD8+) epitope and T helper cell (CD4+) epitope from the HPV-16 
E7 oncoprotein was chosen first. This epitope combination makes 8Q an ideal candidate to 
stimulate efficient immune responses. Moreover, it has been already reported that a construct 
possessing this epitope causes significant reductions in the size of TC-1 tumors (murine C57BL/6 
lung epithelial cells transformed with HPV-16 E6/E7 and ras oncogenes). A short series of modified 
epitopes were designed to avoid uncontrolled aggregation via disulfide bond formation of the 
cysteine-rich 8Q epitope. These epitopes were conjugated to a 4-arm star-polymer and self-
assembled into particles under aqueous conditions. A conjugate that contained the 8Qmin 
(QAEPDRAHYNIVTF; E744-57) epitope was able to reduce and/or eradicate E7-expressing TC-1 
tumors in mice after a single immunization, without the use of an external adjuvant. Next, in order 
to study the mechanism of induction of immune responses by the conjugates, in vivo antibody 
depletion experiments and in vitro uptake of conjugates by antigen presenting cells (APCs) were 
performed. It was found that the conjugates were promptly taken up by APCs (including dendritic 
cells and macrophages) and CD8+ CTLs played a major role in anti-tumor immunity upon 
administration of polymer-peptides conjugates.   
 
The structure-activity relationship of polymer-peptide conjugates against cervical cancer was 
further studied. The most promising epitope 8Qmin was conjugated to a variety of polyacrylate 
polymers including linear, star and dendritic structures to create an efficient self-adjuvanting system 
for peptide-based therapeutic vaccines. The new conjugates had a significantly higher anti-cancer 
efficacy than the antigen formulation, which included a commercial adjuvant. In addition, the 
polymer-peptide conjugates were promptly taken up by APCs where they efficiently activated 
CD4+ T helper cells and CD8+ CTLs. 
 
In conclusion, a synthetic pathway to produce polymer-peptide conjugates as macromolecular 
vaccine candidates against HPV-related cancers was established. The conjugates produced a 
therapeutic effect against established tumors in a mouse model without the help of any external 
adjuvant. Thus, this delivery system overcomes the poor immunogenicity of peptide-based 
vaccines. Furthermore, this polymer-based delivery system demonstrated a therapeutic effect after 
only a single-dose immunization. These findings suggest that this new polymer-peptide conjugate 
approach has great potential for the development of not only therapeutic vaccines against cancers 
but also for other T cell-inducing vaccines against a targeted disease. 
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Chapter One	  
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
1.1 Cervical cancer 
Every year about half a million women are diagnosed with cervical cancer and approximately 
250,000 women worldwide die from the disease [1]. The majority (80%) of all cervical cancer cases 
occur in developing countries [2]. Cervical cancer and its precursors have been identified as near 
100% attributable to various types of human papillomavirus (HPV) infection [3]. There are over 
100 identified types of HPV, which are classified as low-risk, high-risk, and potentially/probably 
high-risk due to their oncogenic potential [4]. Among the various types of HPV, two high-risk 
genotypes, HPV type 16 and HPV type 18, are responsible for more than 50% and 20% of all 
cervical cancers, respectively [5, 6]. Although advances in the field of cancer treatment including 
surgery, chemotherapy and radiotherapy are notable for patients who are diagnosed with early-stage 
cancer, many patients still succumb to the disease. It is therefore important to discover and develop 
more effective therapies against cervical cancer.  
 
1.2 Vaccination 
Vaccination is one of the most effective public health interventions, and offers a promising 
alternative method for the prevention and treatment of virus infections and cancer [7]. Currently, 
two prophylactic HPV vaccines, Gardasil® and Cervarix®, have been commercialized and are 
clinically effective in preventing HPV infection when administered prior to the commencement of 
sexual activity [8]. Although, the existing prophylactic vaccines protect the host against viral 
infection, they are not designed to kill tumor cells. A large proportion of the global population has 
already been infected and cannot be protected by these vaccines. The time between virus infection 
and tumor development is typically one to two decades, thus the long-term efficacy of the new HPV 
vaccines can only be evaluated decades after executing prophylactic vaccination, and global 
coverage of the prophylactic vaccine may not be achieved in the near future [9]. These limitations 
have prompted research into development of therapeutic vaccines that are able to cure HPV-related 
cancers.  
 
Therapeutic vaccine candidates against HPV-related cancers usually have been designed to 
stimulate the production and activation of T cells to develop cytotoxic anti-tumor specific responses 
by targeting the HPV type 16 E7 oncoprotein. This protein is constitutively expressed in cervical 
cancer cells and is required for the induction and maintenance of tumor growth. Peptide-based 
vaccines have been considered as a highly promising strategy for the development of therapeutic 
vaccines in terms of induction of cellular immunity. T cells rapidly and specifically kill cells that 
present as short peptide sequences (T cell epitopes) bound to major histocompatibility complex 
(MHC) molecules [10]. This approach to treating cancer overcomes the serious side effects of 
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classical chemotherapy. Therapeutic vaccines use the body’s natural defense system, and very 
rarely cause significant side effects.  
 
1.3 Peptide-based subunit vaccines 
Traditional vaccines are based on whole pathogens, while modern vaccines usually incorporate the 
smallest antigenic components necessary to induce the desired immune response. Although most 
new vaccines are based on recombinant proteins, the use of minimal immunogenic components is a 
growing field within vaccine design. These components usually comprise short segments of either 
antigenic proteins/peptides (e.g., vaccine against hookworm [11]) or, less commonly, carbohydrates 
(e.g., vaccine against pneumococcal infection [12]). Peptide vaccines possess several advantages 
over classical or whole protein-based approaches. Peptide vaccines (a) can be designed to recognize 
certain pathogen-associated targets which do not need to be immunodominant in nature; (b) do not 
include unnecessary components, drastically reducing the risk of autoimmune or allergic responses; 
(c) do not have the potential to cause infection and their production does not require the use of 
microorganisms; (d) can be produced under good manufacturing practices (GMP) with relative 
ease; (e) are normally water-soluble and stable without requiring maintenance of ‘cold chain’ 
storage; and (f) can include multiple peptide epitopes derived from different stages of pathogen 
growth or even from different pathogens [10]. Although use of the minimal antigenic component 
(epitope) is desirable, the ability of a peptide vaccine to induce an appropriate response is usually 
very weak because it lacks a ‘danger’ signal (e.g., bacteria-specific cell wall lipids that are 
recognized by antigen presenting cells [APCs]) [13, 14]. In addition, peptides alone are rapidly 
degraded in vivo. Therefore, peptide vaccines require the use of an additional adjuvant 
(immunostimulant or immune potentiator) and/or carrier molecules to boost their antigenicity. 
Furthermore, vaccines must often be delivered as a series of doses to stimulate a significant and 
lasting immune response. Although vaccines were discovered more than two centuries ago, a very 
limited number of adjuvants have been approved for human use because they are commonly toxic 
[15]. Therefore, there is strong interest in developing new adjuvants or self-adjuvanting delivery 
systems that trigger strong immune responses against incorporated epitopes and essentially do not 
cause any side effects. 
 
1.4 Particle-based adjuvants 
Particles with sizes ranging from nano to micrometers have been investigated as potential immune 
adjuvants [16, 17]. In the literature, the properties of particulate carriers as vaccine adjuvants have 
been attributed to a number of aspects. First, an antigen in particle form is more likely to be taken 
up by APCs than its soluble form, thus particulate antigens can improve immune responses through 
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enhancing antigen uptake [18, 19]. Secondly, particulate antigen carriers may also act as depots 
(i.e., retaining and slow release of an antigen at the injection site) for continuous antigen release, 
thus increasing the duration of antigen exposure to the immune cells. It has been proven that 
prolonged antigen release can enhance not only the level, but also the quality of immune responses 
[20, 21]. A third function of particulate vaccines is that they can potentially cross-present antigen. 
This is especially important for the initiation of the CD8+ T cell immune responses, which is the key 
role for therapeutic vaccines against cancer and viral infections [22, 23]. Finally, the particle-based 
formulation provides some protection against enzymatic degradation [24], which is important for 
highly susceptible peptide antigen delivered to immune cells. 
 
1.5 Polymer-based vaccine delivery 
Polymer-based drug delivery systems recently attracted attention because it was discovered their 
biological properties and stability in biological fluid could be adjusted. They could also protect an 
incorporated drug from biodegradation and, in general, showed a good safety profile. More 
recently, polymers have been incorporated in vaccine delivery systems as they (a) may form 
biodegradation-resistant materials, which remain in the body forming a depot, thus presenting the 
incorporated antigen to the immune system for an extended time; (b) can form nano- or micro-
particles for size-dependent activation of the immune system; (c) increase stability of incorporated 
antigen during vaccine production and in the biological environment; and (d) allow adjustment of 
controlled release properties [13]. Several groups previously have demonstrated that polymeric 
beads covered by peptide epitopes triggered strong humoral immune responses (antibody 
production) and cellular (CTL activation) immune responses, and that these responses were size 
dependent [25, 26]. The importance of the size can be explained by the ability of small particles to 
travel in the lymphatic system and accumulate in lymphatic nodes while large particles can 
accumulate at the injection site forming a depot effect. Antigen uptake by different classes of APCs 
such as macrophages or dendritic cells (DCs) is also affected by antigen size [27, 28].  
  
1.6 Self-assembled particles 
Molecular self-assembly, often found in biological systems, is defined as the spontaneous 
arrangement of molecules in a pre-determined manner. For example, amphiphiles spontaneously 
form vesicles in solution. As a result, liposomes composed of naturally occurring amphiphiles are 
probably the most studied artificial vesicles used in drug and vaccine delivery [29]. Self-assembly is 
used in nanotechnology to create supramolecular structures from simpler building blocks while 
avoiding the formation of stable covalent bonds. These structures are more likely to biodegrade and 
therefore, are safer for pharmaceutical application than covalently bound equivalents (e.g., 
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polymeric beads). Self-assembled nanoparticles based on amphiphilic polymers are currently under 
intensive investigation [30] and their application for drug delivery is rapidly growing [31]. 
Recently, self-assembled polymer-peptide chimeras have been proposed as a potentially promising 
vaccine delivery system [32].  
 
1.7 Polyacrylate polymer for peptide-based vaccine delivery 
The choice of appropriate polymer must have regard to toxicity, stability of polymer, ability and 
level of releasing antigen, and stability of the antigen during the incorporation process [13]. Here, 
polyacrylate was selected as the most promising candidate for vaccine delivery as polyacrylic acid 
and its esters are easy to synthesize, have very limited toxicity and were reported to possess 
adjuvanting activity when mixed with an inactivated virus [33, 34]. In addition, their safety profile 
is well-established and analogs of polyacrylate have been used since the 1960s for pharmaceutical 
purposes [35].  
 
Recently, polyacrylate polymer was applied to develop peptide-based vaccines that were able to 
induce humoral immune responses against Group A Streptococcus (Streptococcus pyogenes or 
GAS) [36-38]. A minimal B-cell epitope, named J14, from the conserved helical region of GAS M-
protein was chosen as the antigen. Epitope J14 was synthesized and conjugated to the polyacrylate 
dendritic polymer D8 to produce D8-J14 conjugate [36]. Upon self-assembly in water the 
amphiphilic hybrid constructs formed spherical nanoparticles with a diameter of ~ 20 nm and a 
narrow size distribution. Induction of native α-helical conformation of the epitope was observed 
upon conjugation of J14 to the polymer. Analysis of the particles using immunogold labeling 
technique verified the presence of the helical J14 peptides on the surface of the self-assembled 
particles. A high level of antibody production, comparable to positive controls (J14 emulsified with 
complete Freund’s adjuvant), was observed after multiple subcutaneous immunizations in mice. 
Intranasal delivery of the vaccine candidate also triggered strong systemic immune responses and 
the resultant antibodies were found to have opsonic activity toward GAS [37]. Linear polymer L2 
was designed and synthesized to determine the influence of polyacrylate structure on the size of the 
nanoparticles [38]. Epitope J14 was conjugated to the polyacrylate linear polymer L2 to produce 
L2-J14 conjugate. After conjugation and self-assembly of the polymer-peptide chimeras, large 
nanoparticles of L2-J14 (~ 500 nm) were produced. Additional immunological evaluations of the 
two constructs (D8-J14 and L2-J14) were performed using a single immunization approach, which 
is uncommon in peptide-based vaccines. A single dose vaccination protocol is clearly preferred as a 
mass vaccination strategy, especially in developing countries where infrastructure is limited. 
Despite administering a lower amount of total immunogen, both constructs induced strong immune 
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responses in mice. High J14-specific IgG titres were again observed for D8-J14 nanoparticles, 
while a significantly lower response was detected for L2-J14. These findings support the 
suggestion that smaller nanoparticles travel more easily to lymphatic nodes and therefore induce 
stronger humoral immune responses [27]. No toxic side effects were observed in the immunized 
mice making this system an excellent self-adjuvanting delivery platform to trigger strong humoral 
immunity against short peptide epitopes. 
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1.8 Research aims and hypothesis  
 
1.8.1. Hypothesis 
Despite promising preclinical and clinical results, therapeutic HPV vaccines struggle with the lack 
of suitable delivery/adjuvanting systems to achieve full potential in eradicating HPV-associated 
cancers. To overcome this problem, appropriately designed polymer conjugated to synthetic 
peptides epitopes derived from HPV-16 E7 oncoprotein can self-assemble to create particles that 
mimic natural human pathogens. These particles can be used to produce a therapeutic self-
adjuvanting anti-cancer vaccine (Figure 1). 
 
 	  
Figure 1. Well-defined polymers (blue highlight) conjugated to peptide epitopes (green highlight) 
self-assemble into particles that can be used to develop a self-adjuvanting anti-cancer vaccine. The 
particles are expected to take up by APCs, which will activate CD4+ T helper cells, and CD8+ CTLs 
to induce cellular immunity against cancer.  
 
1.8.2. Overall aim  
The aim of this project was to develop a safe and potent anti-cancer vaccine delivery strategy using 
unique polymer-based immunogenic particles. The polymer-peptide conjugates would be able to 
eliminate tumor in a mouse model. 
 
1.8.3. Specific aims 
1.8.3.1. The first specific aim was to establish a synthetic and self-assembly pathway for the 
polymer-peptide conjugates. Each construct contained multiple copies of a single immunogenic 
peptide conjugated to a polymer. 
This aim included: 
• Design of peptide epitopes and optimization of synthesis of their azide analogues. 
• Identification of the optimal conditions for conjugation of peptide epitope to polymer core. 
• Optimization of self-assembly process of produced conjugates. 
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 1.8.3.2. The second aim was to perform physicochemical characterization of the produced particles 
including particle size analysis and epitope-substitution ratio for each conjugate. 
 
1.8.3.3. The third aim was to subcutaneously immunize mice with the conjugates without any 
additional adjuvant, and to investigate the therapeutic immune responses in a mouse model of 
cervical cancer.  
 
1.8.3.4. The fourth aim was to characterize the immunological properties of the polymer-peptide 
conjugates in order to investigate the mechanism of induction of immune responses by the particles. 
The biological evaluation included: 
• In vitro uptake of conjugates by APCs, including DCs and macrophages. 
• In vivo antibody depletion experiments. 
• In vivo activation of CD4+ and CD8+ T cells by conjugates. 
 
1.9 Thesis outline 
In the chapters that follow, Chapter 2 includes a review article. All research data are presented in 
Chapters 3-5 in the form of published or prepared manuscripts. The last chapter comprises 
conclusions and suggestions for further study. 
 
Chapter 2 comprises an introduction to HPV infections and cervical cancer as well as a review of 
the strategies applied for the development of therapeutic peptide-based vaccines against HPV 
infections. This review highlights selected promising vaccine formulations tested in preclinical 
models and clinical trials for the treatment of HPV-associated cancers, and summarizes the 
prospects of peptide subunit vaccines for the control of HPV-related malignancies. 
 
Chapter 3 is a published research article describing the design and synthesis of three polymer-
peptide constructs, and an in vivo biological evaluation of each conjugate. The improvement of 
synthesis of peptide epitope candidates by changing the standard Solid-Phase Peptide Synthesis 
(SPPS) procedure and utilizing the isopeptide method is discussed. The conditions for conjugation 
and processing of self-assembled conjugates into particles are also described. In vivo tumor 
treatment experiments were performed using mice implanted with TC-1 tumor cell line, who were 
then vaccinated with tested formulations to assess the therapeutic activity of each polymer-peptide 
conjugate. Based on this immunological assessment, the most effective epitope was found and 
chosen for future study. 
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 Chapter 4 includes a published article that identifies the immunological properties of the most 
promising polymer-peptide conjugate (according to the previous Chapter 3 study) via in vitro APCs 
(including DCs and macrophages) uptake and in vivo antibody depletion experiments. The latter 
experiments were performed by depletion of CD8+, CD4+ or NK cells. The ability of uptake of 
conjugate by DCs and macrophages, and which subset of lymphocytes contributes mostly to the 
therapeutic immunity in this in vivo model are illustrated in this chapter. 
 
Chapter 5 is a submitted paper and describes different designs of polyacrylate polymers including 
linear, star and dendritic structures conjugated to the same peptide epitope, and their in vitro and in 
vivo biological properties. In vivo biological evaluation in this study includes tumor challenge 
experiments and the level of activation of CD4+/CD8+ T cells by each conjugate. In vitro analysis of 
APCs (including DCs and macrophages) uptake for all conjugates is also included. This article 
focuses on studying the structure-activity relationship of polymer-peptide conjugates to find an 
efficient self-adjuvanting system for peptide-based vaccines that is able to stimulate adequate T cell 
responses. The properties of different conjugates including physicochemical characterization and 
biological assessment are discussed in this article. 
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Review of Literature 
 
 
 
“Advances in peptide-based human papillomavirus therapeutic vaccines” 
 
Liu, T. Y.; Hussein, W. M.; Toth, I.; Skwarczynski, M., Advances in peptide-based human 
papillomavirus therapeutic vaccines. Curr. Top. Med. Chem., 2012, 12, 1581-1592. 
 
 
2.1 Introduction to this publication 
This chapter was published in Current Topics in Medicinal Chemistry as a review article. Peptide-
based vaccines are a promising strategy for the development of therapeutic HPV vaccines due to 
their safety, stability, and ease of production. This review summarizes the prospects of peptide-
based vaccines for the treatment of established HPV infections. We address the challenges that 
scientists currently face for developing peptide-based vaccines and explore feasible strategies for 
improving the potency of the induced immune response with the aim of treating established HPV 
infections. 
 
2.2 Reprint of this peer-reviewed publication 
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Abstract: Cervical cancer is the second leading cause of cancer in women worldwide. Human papillomavirus (HPV) is 
responsible for all cases of cervical cancer. Commercial prophylactic HPV vaccines are now available, but unfortunately 
these vaccines have no therapeutic effect against established HPV infections. In order to accelerate the control of cervical 
cancer and treat established HPV infections, it is necessary to develop therapeutic vaccines to eradicate HPV by generat-
ing cell-mediated immunity against HPV infected cells. Two HPV-encoded early proteins, the E6 and E7 oncoproteins, 
are the preferred targets because they are consistently expressed in virtually all cervical cancer cells and are necessary for 
the induction and maintenance of HPV-associated disease. A variety of vaccine strategies have been employed targeting 
immune responses to these proteins. Peptide-based vaccines are a promising strategy for the development of therapeutic 
HPV vaccines because of their safety, stability, and ease of production. This review summarizes the prospects of peptide-
based vaccines for the treatment of established HPV infections. We address the challenges that scientists currently face for 
developing peptide-based vaccines and explore feasible strategies for improving the potency of the induced immune re-
sponse with the aim of treating established HPV infections. 
Keywords: Peptide subunit vaccine, anticancer vaccine, therapeutic vaccine, cervical cancer, human papillomavirus, HPV-16. 
INTRODUCTION 
 Every year cancer of the cervix (cervical cancer) is diag-
nosed in about 500 000 women, causing approximately 250 
000 deaths annually [1, 2]. The high-risk types of human 
papillomavirus (HPV) are associated with over 80% of cer-
vical cancers through epidemiological and experimental 
studies [3]. Two high-risk types, HPV type 16 (HPV-16) and 
HPV type 18 (HPV-18), are responsible for up to 50% and 
20% of all cervical cancers, respectively [4]. The traditional 
detection of cervical pre-cancers by cervical cytological 
screening using the Papanicolaou (Pap) smear test has dra-
matically reduced the incidence of cervical cancer in the 
developed world due to early intervention with therapy. 
However, underdeveloped countries are unable to implement 
comprehensive screening-based programs, so early detection 
and treatment of cervical pre-cancers is very limited [5, 6]. 
Patients who are diagnosed with early-stage disease can be 
treated with surgery, radiotherapy, or chemotherapy, but 
many patients still succumb to the disease [6, 7]. It is there-
fore necessary to develop more effective therapies for the 
treatment of cervical cancer.  
 Immunotherapy is a promising strategy for the treatment 
of established HPV infection and cervical cancer. The newly 
licensed prophylactic HPV vaccines, Gardasil® and Cer-
varix®, use HPV virus-like particles (VLPs) to generate neu-
tralizing antibodies against the L1 (major) capsid protein. 
These vaccines are predicted to decrease the morbidity of 
cervical cancers by approximately 70% [8-11]. Despite the 
successful prophylactic effects of these vaccines, the high 
*Address correspondence to this author at the School of Chemistry &  
Molecular Biosciences, University of Queensland, Chemistry Blg #68,  
St. Lucia, Qld 4072; Tel: (617) 33469892; Fax: (617) 3365 4273;  
E-mail: i.toth@uq.edu.au 
cost, cold storage requirement, and availability of the exist-
ing prophylactic HPV vaccines are important limitations to 
the widespread delivery of these vaccines in developing 
countries. Thus, the prevalence and associated morbidity of 
cervical cancer may not be significantly reduced worldwide 
[12-14]. Prophylactic HPV vaccines that target the L1 capsid 
have no therapeutic effect on established HPV infection. 
This is because HPV-infected basal epithelial cells and cer-
vical cancer cells do not express detectable levels of L1 cap-
sid antigen. The time between virus infection and tumor de-
velopment is typically 10-20 years, so a large proportion of 
the global population is already infected and cannot be 
treated by the prophylactic vaccine [11, 12, 15, 16]. To com-
bat established infections, it is necessary to develop a thera-
peutic vaccine against high-risk HPV, particularly HPV-16 
and HPV-18 strains [17-19].  
 The foremost aim when developing a therapeutic HPV 
vaccine is the treatment of existing HPV infections. Many 
therapeutic HPV vaccine candidates were designed to elicit 
the production and activation of T cells to develop cytotoxic 
anti-tumor specific responses by targeting the E6 and/or E7 
oncoproteins. Current therapeutic vaccine strategies include: 
live vector-based (viral vectors/bacterial vectors), nucleic 
acid-based (DNA/RNA), cell-based (dendritic cells/tumor 
cells), protein-based, and peptide-based vaccines. Among the 
various immunotherapeutic delivery systems, peptide-based 
vaccines are simple, stable, well tolerated and can be tailored 
to produce the desired immunogenic effects (Fig. 1) [20-22]. 
Since T cells can recognize tumor-associated antigens in the 
form of short peptides bound to major histocompatibility 
complex (MHC) molecules, vaccination with peptides de-
rived from HPV antigens provides a feasible strategy for 
immunotherapy against HPV infections [23, 24]. Identification 
of tumor-reactive T lymphocyte peptide epitopes is necessary
13
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Fig. (1). Relationship between antigen presenting cells and humoral and cellular immunity. (a) APCs uptake the immunogen, process it into 
peptide epitopes, and present it on MHC class I and/or class II molecules on the cell surface. T cell receptors of T helper cells (CD4+ T cells) 
interact with the Th-epitope/MHC II complex. (b) Following activation of Th cells and B cell maturation, antibody secretion occurs. (c) Naive 
CD8+ T cells can be stimulated through the interaction of activated Th cells with certain types of APC. (d) CTLs have the ability to recognize 
and kill target cells that display viral or tumor peptides. These CTLs are generated from naive CD8+ T cell through the interaction with acti-
vated APC carrying above peptide epitopes on MHC class I molecules [25].
before a vaccine can be developed. Peptide-based vaccines 
have the potential advantages of combining multiple epi-
topes to enhance peptide-MHC binding and improve specific 
T cell-mediated immunity against HPV-infected cells [25]. 
However, selection of the most appropriate T cell epitopes 
able to elicit responses by antitumor cytotoxic T lympho-
cytes (CTLs) and helper T lymphocytes (HTLs) remains a 
challenge. Another limitation is that peptide-based vaccines 
have low immunogenicity. Many developments in the use of 
peptide-based vaccines have focused on enhancing vaccine 
potency by using adjuvants (immune stimulating agents) to 
circumvent this problem [26]. This review summarizes the 
prospects of peptide-based vaccines for the treatment of es-
tablished HPV infections. We address the obstacles that sci-
entists currently face in developing peptide-based vaccines 
and explore feasible strategies for improving the potency of 
inducing immune responses leading to the treatment of HPV 
infections.  
THE BIOLOGY OF HPV INFECTION IN THE CER-
VIX  
 In order to develop an optimal therapeutic vaccine 
against HPV, it is necessary to fully understand the progres-
sion from HPV infection to cervical cancer. HPV belongs to 
a genus in the Papovirus family and is a non-enveloped, 
double-stranded, closed circular DNA virus. The HPV ge-
nome is approximately 8,000 base pairs, encoding six early 
proteins (E1, E2, E4, E5, E6, and E7) and two late proteins 
(L1 and L2) [27]. The early genes encode non-structural pro-
teins, regulating viral gene replication and transformation, 
whereas two late genes (L1 and L2) encode the viral capsid 
proteins. E1, E2, and E4 proteins contribute to viral gene 
replication, transcription, and genome amplification, respec-
tively. The E5, E6, and E7 proteins interact with growth fac-
tor receptors, binding to and inactivating the tumor suppres-
sor gene products p53 and retinoblastoma (pRb), respec-
tively [28, 29]. Interactions between HPV proteins and the 
host cell result in dysregulation of cell cycle control, eventu-
ally leading to the development of cervical cancer.  
 The infection of the cervical epithelium with HPV is 
closely associated with the maturation of keratinocytes  
(Fig. 2). After infection with HPV in the basal layer of the 
epithelium, the viral early proteins are expressed, and inter-
act with cellular proteins to regulate viral replication. Next, 
the infected basal cells move up from the basement mem-
brane to the upper epithelial layers as epithelial cell differen-
tiation occurs, expressing E4 protein for viral amplification. 
Finally, a subset of E4-positive cells express the late proteins 
L1 (major) and L2 (minor), and L1 and L2 assemble to form 
the new infectious virions. Therefore, mature virions are 
released only by the superficial epithelial keratinocytes [27].  
 Integration of the viral episome into the host DNA occurs 
in cells infected with high risk HPV. This often results in the 
deletion or inactivation of some early (E2, E4 and E5) and 
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late (L1 and L2) genes, while the E6 and E7 genes are con-
sistently expressed within infected cells [13, 14]. The viral 
E2 gene is a negative regulator of E6 and E7 expression. 
Subsequently, interruption of E2 gene leads to over expres-
sion of the E6 and E7 genes [30]. In addition, the E6 and E7 
genes are able to bind and complex with the tumor suppres-
sor gene products, p53 and retinoblastoma (pRb) protein, 
respectively. p53 and pRb have tumor-suppressive and cell 
cycle growth inhibitory functions [31, 32]. Thus, over-
expression of E6 and E7 oncoproteins results in the dysregu-
lation of the cell cycle, causing cellular transformation which 
leads to the development of cervical intraepithelial neoplasia 
(CIN) that may eventually progress to cervical cancer [33]. 
HUMORAL IMMUNE RESPONSES AND CELL-
MEDIATED IMMUNE RESPONSES TO HPV INFEC-
TIONS 
 It is estimated that over 98% of HPV infections resolve 
spontaneously. Nevertheless, the natural immune response to 
HPV after infection is weak, and the clearance of infected 
cells is much slower, when compared with that of most other 
viral infections [34, 35]. Animal studies indicated that, when 
expressed, the major capsid protein (L1) of HPV elicits vi-
rus-neutralizing antibodies that can protect the host from 
HPV infection. Humoral antibody responses to the capsid 
proteins were weak, and measurable immune responses were 
only observed in about 50% of subjects with a persistent 
HPV infection [36]. The L1 (major) capsid protein has been 
used to produce virus like particles (VLPs), currently em-
ployed in the marketed prophylactic anti-HPV vaccines. Ac-
cording to serological studies based on VLPs, in about 50% 
of patients the HPV infection causes a humoral response 
(IgG) against conformational epitopes of the L1 (Major) cap-
sid protein [37, 38], although the duration of measurable 
humoral immunity to HPV capsid proteins following viral 
clearance is unknown. Unfortunately, immunization with 
capsid proteins failed to induce powerful therapeutic effects 
for established HPV infections that had evaded antibody-
mediated neutralization [39]. It is likely that this is because 
the capsid proteins are only expressed in the superficial 
epithelial keratinocytes, but not in basal keratinocytes. Per-
sistent HPV infection is very prevalent and contributes to 
increased morbidity and mortality. An effective vaccination 
strategy is important in order to treat and eradicate cells al-
ready infected with HPV.  
 Vaccines that elicit cell-mediated immune responses to 
nonstructural viral proteins are, in principle, more likely than 
antibody-mediated neutralization to cause the regression of 
established lesions or even cancers. HPV infection fre-
quently induces discrete humoral and cell-mediated immune 
responses [40]. Evidence suggests that cellular immunity, 
particularly a cellular infiltrate of antigen-specific T cells, is 
associated with regression of established HPV infection [41, 
42]. Several observations indicate that cell-mediated immune 
responses are important for the control and eradication of 
established HPV infection [43]:  
1) Humoral immunodeficiency does not predispose HPV-
positive patients to the growth of HPV-associated, pre-
cancerous lesions.  
2) The prevalence of HPV-associated disease is increased 
in patients with reduced CD4+ T cell function, such as 
transplant recipients [44] and human immunodeficiency 
virus (HIV)-infected patients [45, 46].  
3) One study indicated that spontaneous regression of CIN 
is accompanied by a delayed-hypersensitivity response 
to the viral E7 protein mediated by CD4+ T cells infil-
trating the infected epithelium [47].  
4) Cervical tumors contain functionally altered dendritic 
cells (DCs) leading to inhibition of CD8-mediated anti-
gen-specific T cell responses [48].  
5) Immunostimulatory functions mediated by cytokines are 
disabled in HPV-induced tumors [49].  
 These observations support the hypothesis that, although 
humoral immunity induces antibody-mediated neutralization 
to protect the host against initial infection, cell-mediated 
 
Fig. (2). Schematic representation of HPV gene expression during keratinocyte differentiation in the stratified squamous epithelium. After 
infection with HPV in the basal layer of the epithelium, early viral proteins (E1, E2, E4, E6, and E7) are expressed. As the keratinocytes 
mature and progress through the epithelium, the late proteins (L1 and L2) assemble to form the new infectious virions, and mature virions are 
produced only in the most superficial layers of the epithelium. 
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immunity is necessary for the eradication of HPV infection 
and inhibition of tumor progression. Therefore, to be effec-
tive, a therapeutic HPV vaccine must be able to stimulate 
enhanced HPV-specific cell-mediated immune responses. 
 The host antigen presenting cells (APCs) are an appro-
priate target for a therapeutic HPV vaccine (Fig. 1). Many 
studies report that professional APCs (including dendritic 
cells, macrophages, and B cells) were critical components in 
mediating immunotherapy. Dendritic cells (DCs) are potent 
professional APCs that initiate epithelial immune responses 
by priming helper T cells and killer T cells in vivo [50-52]. 
Langerhans cells (LCs), specialized DCs of the epidermis, 
capture antigens and present large numbers of immunogenic 
MHC-peptide complexes on their surface [53, 54]. Then, 
LCs migrate to the lymph nodes where they present antigen 
collected in the epithelium directly to the antigen-specific T 
cells [55]. DCs highly express MHC-I and MHC-II mole-
cules and co-stimulatory molecules that are involved in anti-
gen-specific T cell activation. DCs up-regulate the expres-
sion of MHC-I and MHC-II molecules and adhesion mole-
cules and become more potent stimulators of T cell-mediated 
immunity through maturation-inducing stimuli such as in-
flammatory cytokines [39]. Effective therapeutic vaccines 
must have a two-fold effect: targeting tumor antigens to pro-
fessional APCs, and enhancing MHC-I and/or MHC-II pres-
entation of the tumor antigen to activate antigen-specific T 
cells.  
 Persistent HPV infection is a consequence of the natural 
anti-cancer immunity failing to eliminate the infected cells 
[56]. The HPV early proteins play a pivotal role in evasion 
of the host immune system through a variety of mechanisms:  
1) The HPV-16 E7 oncoprotein has high homology with 
several human proteins [57], which may facilitate rec-
ognition as autoantigen.  
2) The E6 oncoprotein inhibits the interactions between 
epithelial cells and DCs [58], possibly accounting for 
the depletion of DCs observed in the HPV-infected cer-
vical epithelium [59]. An E6 oncoprotein-mediated re-
duction in expressed interleukin-8 (IL-18) CD8+ was 
also observed [60].  
3) The E6 and E7 oncoproteins down-regulate the produc-
tion and responsiveness of infected cells to type 1-
interferons (IFNs) [61, 62]. Both E6 and E7 oncopro-
teins inhibit IL-18-induced IFN- in natural killer (NK) 
cells [63]. Additionally the E7 oncoprotein arrests the 
antiviral signaling mediated by interferon-alpha (IFN-)
[64, 65] and has also been observed to inhibit the IRF-1-
mediated activation of the IFN- promoter [66].  
4) Extracellular E7 oncoprotein potentially has the ability 
to inhibit T cell responses [67].  
5) The E5 oncoprotein binds the 16-kDa subunit of vacuo-
lar proton-ATPase and disturbs its activity, inhibiting 
pH-dependent processing of antigenic peptides, which 
may interfere with proper antigen presentation [68-70].  
 Cervical cancer has been shown in the past to inactivate 
the type 1 interferons (IFNs), cytokines such as IL-18, and 
antigen processing and presentation. A recent study has re-
vealed that cervical extracts, in particular the protease com-
ponent, can suppress lympho-proliferative responses [71], 
whereas expression of FasL on cervical tumors can cause 
apoptosis of the infiltrating lymphocytes [72]. These results 
also indicate that the production of regulatory T cells may be 
an important suppressive mechanism in cervical cancer [73, 
74], because regulatory T cells suppress the induction of type 
1-helper T (Th1) cells [75], and IFN--producing Th cells are 
required to mobilize CD8+ T cells to the site of HPV infec-
tion [76]. Therefore, a successful immunotherapeutic ap-
proach to cervical cancer must circumvent the activity of 
these cells types and other local immunosuppressive mecha-
nisms.  
THERAPEUTIC HPV VACCINE DEVELOPMENT  
 Therapeutic vaccines that target established HPV infec-
tions aim to generate specific cell-mediated immunity that 
eliminates pre-existing lesions and malignant tumors. A 
therapeutic vaccine should target HPV antigens that are con-
stantly expressed in the infected cells. Thus, in contrast to 
the prophylactic HPV vaccines, therapeutic HPV vaccines 
need to contain an antigenic determinant derived from HPV 
early proteins, such as the E6 and E7 proteins, which are 
expressed throughout the life cycle of HPV [29, 77-80]. 
Since E6 and E7 oncoproteins are required for the induction 
and maintenance of the malignant phenotype of cancer cells 
[81], cervical cancer cells are unlikely to escape immune 
attack targeting these proteins via antigen loss. The E7 pro-
tein is more abundantly expressed and is more highly con-
served than the E6 protein [82, 83]. The E7 protein also in-
duces genotype-specific antibody after the commencement 
of invasive cervical cancer, thus the E7 proteins can generate 
therapeutic and protective effects [82]. Other early viral pro-
teins, the E1, E2, E4, and E5 proteins, also have potential as 
therapeutic vaccine antigens for the treatment of warts. How-
ever, neither the E1 protein nor the E2 protein is constantly 
expressed in HPV-induced carcinoma. Evidence suggests 
that E5 may play a critical role in the genesis of cervical 
cancer but is less important in persistence and progression 
[84]. Therefore, the E5 protein has limited immunogenicity 
and has not been extensively researched as a promising vac-
cine antigen [85]. Similarly, the E4 protein and L1 and L2 
capsid proteins are unlikely to be proper targets for therapeu-
tic vaccine antigens because these proteins are not expressed 
at detectable level in infected basal epithelial cells and cervi-
cal cancer cells [86].  
 In order to treat patients with pre-invasive and invasive 
cervical cancers, therapeutic vaccines need to elicit specific 
cytotoxic anti-tumor responses by targeting CD8+ T cell ac-
tivation via MHC-I restricted antigens. Additionally, CD4+ T 
cell responses, which are MHC-II restricted, are equally im-
portant in both effective anti-viral and antitumor CTL re-
sponses, and lead to destruction of the virus or tumor by 
CD8+ CTLs [87, 88]. The function of CD4+ T cells in the 
priming phase of a tumor specific CTL response is thought 
to occur at the level of activating DCs to allow these cells to 
effectively activate naive CD8+ T cells [89-91]. Conse-
quently, several requirements need to be met for the estab-
lishment of an effective therapeutic vaccine against cervical 
cancers:  
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1) The target antigen must be recognized by the T cells 
rather than by antibodies. 
2) The vaccine should target appropriate APC subsets.  
3) The tumor antigen should induce large number of effec-
tor T cells, including both CD4+ and CD8+ T cells. 
4) Ensure efficient T cell trafficking to the tumor site.  
5) Circumvent the activity of local immunosuppressive 
mechanisms at the tumor site.  
6) Induce strong, long-lasting inflammation at the tumor 
site.  
 Several HPV vaccine strategies have been devised to 
achieve these requirements with different degrees of success. 
Peptide-based vaccines are one of the most promising ap-
proaches to develop a safe and efficient therapeutic vaccine 
to treat HPV-related cancers. 
PEPTIDE-BASED HPV VACCINE DEVELOPMENT  
 Synthetic peptide-based vaccines are potentially excellent 
candidates for rational vaccine development because they are 
naturally non-infectious, completely defined, relatively easy 
to produce, and are generally considered to be safe. Peptide-
based vaccines are well characterized, stable in freeze-dried 
form, and are able to combine multiple epitopes [20, 22, 25]. 
However, their low immunogenicity must first be overcome. 
Another limitation of peptide-based vaccines is the need to 
match the patient’s human leukocyte antigen (HLA). HLA 
polymorphisms in patients make it difficult to develop a pep-
tide-based vaccine that is applicable to the whole population. 
In the case of peptide-based vaccines against HPV, several 
specific CTL epitopes from HPV-16 E6 and E7 have been 
characterized for the HLA-A2 molecule, the most common 
MHC-I molecule in humans [92-94]. Immunization with a 
peptide carrying MHC-I restricted epitopes from E6 and/or 
E7 have been shown to elicit cell-mediated immune re-
sponses in both animal and human models [92, 94]. In addi-
tion to finding an epitope that interacts with the host HLA, 
the design of a peptide-based anti-HPV vaccine relies on the 
accurate identification of an appropriate protective epitope. 
Epitope Selection 
 Epitope identification and selection of most relevant epi-
topes are the initial challenges of peptide-based vaccine de-
velopment. In one of the first anti-HPV peptide studies, Felt-
kamp et al. identified the sequence E749-57 (RAHYNIVTF) 
as an MHC-I binding peptide that can elicit CTL responses 
in HPV 16-induced tumor tissue [95, 96]. Tindle et al. iden-
tified E748-54 (DRAHYNI) as a Th-cell-stimulating epitope 
that helped to elicit antibody responses to HPV-16 E7 in a 
mouse model [97]. Recently, multiple studies have indicated 
that the use of longer versions of CTL peptide epitopes, cov-
ering the Th-cell epitope, ensures the induction of sustained 
CD8+ T cell reactivity in vivo, when compared with using the 
minimal CTL peptide epitope (E749-57) [98, 99]. Extension of 
the CTL peptides to longer variants may offer an excellent 
alternative when external specific CD4+ helper T cell epi-
topes are not readily available [99]. A recent attractive ap-
proach for vaccination has been the use of overlapping long 
peptides as antigens. The use of overlapping long peptide 
vaccines that cover the whole HPV E6/E7 sequence, repre-
senting the complete antigen in several fragments, circum-
vented the need to target a patient’s HLA type. This ap-
proach led to more efficient peptide presentation, minimizing 
peptide-induced tolerance via antigen presentation by non-
professional APCs. This approach has been tested in pre-
clinical mouse [100] and rabbit [98] models, and in clinical 
trials [101-103].  
Vaccine Delivery 
 In general, peptide-based vaccines have weak immuno-
genicity, but the use of adjuvants (immune stimulating 
agents) can boost the immunogenicity of these vaccines [22]. 
A number of adjuvants induce strong immune responses and 
are widely used in animal models (e.g. incomplete Freund’s 
adjuvant, IFA) [95, 100, 104]. However, most experimental 
adjuvants are unsuitable for human use because of serious 
adverse side effects. Some oil-emulsion adjuvants have been 
approved and commonly employed for use in human trials 
(e.g. Montanide ISA 51, a human grade IFA-like adjuvant) 
[101-103, 105-107]. Another strategy to enhance the potency 
of peptide-based vaccines is the conjugation of immu-
nostimulatory lipids to a peptide antigen. Lipidic carriers 
have been used extensively for vaccine delivery and can act 
as self-adjuvanting moieties [108-111]. The lipid core pep-
tide (LCP), a vaccine delivery system incorporating 
lipoamino acids, was used to produce vaccine candidates 
against HPV-16 [104]. Moyle et al. demonstrated that an 
LCP system that incorporated the long sequence E744-62
(known as 8Q) with CTL, T helper cell, and B cell epitopes 
was self-adjuvanting and reduced tumor size. This epitope 
was unable to prevent TC-1 tumors when delivered alone 
[104]. The self-adjuvanting properties of LCP are predomi-
nantly derived from its propensity to target vaccines to DCs 
and induce DC maturation [22, 112]. In another mouse 
study, a lipopeptide vaccine incorporated the E643-57 and 
E744-62 epitopes conjugated to a dipalmitoyl-lysine-glycine-
glycine (Pam2KGG) moiety. It was shown that although both 
epitopes were individually able to elicit specific CTL re-
sponses in mice, the lipid-tailed (Pam2KGG) diepitopic con-
struct was more efficient than the monomeric forms [113].  
 Liposomes have been used extensively to deliver low 
molecular weight drugs, plasmid DNA, oligonucleotides, 
proteins, and peptides as well as for the delivery of peptide-
based antigens. Huang and coworkers developed a liposome-
based, nanoparticle delivery system, called Liposome-
Protamin-DNA (LPD) [114]. LPD is a self-assembled mix-
ture of cationic liposomes, polycations, and plasmid DNA. 
In their early studies, the LPD/E7 formulation (which con-
tains bacterial DNA) showed the potential to eradicate estab-
lished E7-expressing TC-1 tumors. Afterwards, they em-
ployed cationic 1,2-dioleoyl-3-trimethylammonium propane 
(DOTAP) as a potent cancer vaccine adjuvant to form an 
DOTAP/E7 complex, which contained the DOTAP cationic 
lipid and the E749-57 peptide antigen. The DOTAP/E7 formu-
lation has the ability to elicit the activation of DCs without 
plasmid DNA, generate antigen-specific CD8+ T lymphocyte 
responses, and eradicate established E7-expressing TC-1 
tumors after a single immunization. Huang’s group has im-
proved vaccine formulation by incorporating an E7-
lipopeptide, instead of the native E7 peptide, into the DO-
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TAP liposome [114]. The lipopeptide consists of an N-
terminal - or -palmitoyl lysine connected to the E7 peptide 
via a dipeptide Ser-Ser linker. The presence of the dipeptide 
linker sequence between the E7 peptide and the attached 
fatty acid was necessary to stimulate a full immune response. 
The DOTAP/E7-lipopeptide formulation was more than 
twice as potent as the DOTAP/native E7 formulation [114]. 
Another liposome strategy employed an adjuvant in which 
gangliosides are incorporated into the outer membrane pro-
tein complex of Neisseria meningitides to form very small 
size proteoliposomes (VSSP) for DC activation and Th 1 
differentiation. This was the first study to show that VSSP 
with a minimal CTL (E749-57) epitope could be used as an 
anti-cancer immunotherapy by inducing an E7-specific CD8+
T cell response [115]. 
 Other popular adjuvants used for peptide-based vaccines 
include two strong DC-activating agents: an oligodeoxynu-
cleotide (ODN)-CpG [85, 100, 116-118] and a monophos-
phoryl lipid A (MPL) [100]. A recombinant cytokine, e.g. 
granulocyte-macrophage colony-stimulating factor (GM-
CSF), can be used as an adjuvant for augmenting immuno-
genicity in peptide-based vaccines [100, 119]. In one of the 
latest studies, a self-assembled nanoparticle HPV vaccine 
was designed to combine the cell-penetrating peptide, HIV-1 
Tat 49-57, that was fused with the minimal CTL (E749-57)
epitope and GM-CSF[119]. This vaccine generated potent, 
long term, anti-tumor immune responses through the produc-
tion of long lasting memory CD8+ cells. Another pre-clinical 
study employed an E743-77 long peptide, containing both CTL 
and Th epitopes, and several DC-activating adjuvants, in-
cluding GM-CSF, ODN-CpG and MPL, for the optimal 
priming of tumor-specific CTLs. Vaccination with the long 
peptide led to the induction of CD8+ CTL and CD4+ Th cells. 
CD4+ Th cells contribute to the level of the induced E7-
specific CD8+ CTL cells responses by delivering essential 
activation signals to DCs. It was suggested that the long pep-
tide was preferentially endocytosed, processed and presented 
by professional APCs, and this could circumvent the poten-
tial hazard of peptide-induced tolerance. The potency of the 
vaccine was further augmented by the use of DC-activating 
adjuvants, notably ODN-CpG. Synthetic ODN-CpG mimics 
bacterial DNA and binds toll-like receptor (TLR)-9 provid-
ing a “danger signal” to activate the immune response [120]. 
Therefore, vaccination with a long peptide containing CD8+
CTL and CD4+ Th cell epitopes, and DC-activating agents 
could augment the immunity generated against peptide-based 
HPV vaccines [100]. A similar long peptide and adjuvant 
combination was also trialed in the cottontail rabbit papillo-
mavirus (CRPV) preclinical model of persistent HPV infec-
tion. Overlapping long E6 and E7 peptides, which contained 
both CD4+ T helper and CD8+ CTL epitopes, administered 
with the mixture of Montanide ISA 51 and ODN-CpG were 
tested for therapeutic efficacy against CRPV-infected le-
sions. After vaccination, this overlapping long vaccine was 
able to significantly control wart growth in rabbits [98]. An-
other animal study, which used a long peptide (E744-62) and 
the DC-activating adjuvant ODN-CpG, has identified that 
vaccination with a longer peptide containing CTL and Th 
cell epitopes, and ODN-CpG represents a promising strategy 
against MHC-I deficient tumors. This study also investigated 
the efficacy of cellular vaccines based on ex vivo cultured 
DCs pulsed with either minimal CTL (E749-57) epitope or 
longer CTL (E744-62) epitopes, and then matured with ODN-
CpG. The use of ex vivo cultured DCs is particularly suitable 
for the delivery of peptide-based vaccines. Peptide antigens 
directly loaded onto the ex vivo activated autologous DCs 
can bypass the processing requirement and allow the accu-
rate delivery of peptide antigens to trigger immune re-
sponses. It was revealed that longer peptides presented by ex 
vivo cultured DCs resulted in stronger inhibition of tumor 
growth than the shorter epitopes [116].  
 In recent years, several novel vaccine delivery platforms 
were developed for augmenting the immunogenicity of pep-
tide-based vaccines. Daftarian and coworkers encapsulated 
antigens and adjuvants in multilamellar liposomes in a wa-
ter-in-oil emulsion, VacciMax (VM) [117]. VM is a 
liposome-based antigen delivery platform containing the Pan 
HLA-DR epitope (PADRE) and ODN-CpG as adjuvants and 
Montanide ISA 51 as the oil carrier of the water-in-oil emul-
sion. PADRE, a universal T helper epitope, was found to 
bind to different MHC-II molecules with high-affinity and 
was used in conjunction with other types of vaccines to in-
crease vaccine potency in preclinical studies [121, 122]. In a 
preclinical study using the C3 tumor model, a single admini-
stration of a minimal CTL (E749-57) epitope via VM 
liposome-based antigen delivery induced a long-lasting CTL 
response, complete protection against tumor challenge, and 
rapid tumor eradication. All mice that received this vaccine 
remained tumor-free when re-challenged with C3 cells [117]. 
To extend these results to a more clinically appropriate HPV 
cancer model, TC-1/A2 tumor cell lines in aged HLA-A2 
transgenic mice (48-58 weeks old) were employed for fur-
ther study. A VM formulation containing peptide antigens 
derived from E7 and E6 as either a physical mixture or 
chemically conjugated generated a strong CTL response. The 
VM-formulated therapeutic vaccine induced potent immune 
responses that could eradicate large transplanted tumors (>
700 mm3) in aged mice less than three weeks post-
immunization with a single vaccination. Therefore, VM is a 
promising vaccine delivery platform for the therapeutic 
treatment of cervical cancer [118].  
 Another animal study, using a similar strategy, combined 
the PADRE peptide (to enhance CD4+ Th cells responses) 
and a TLR ligand (to enhance DC activation) to boost the 
immunogencity of peptide-based vaccines [123]. Wu and co-
workers designed a therapeutic vaccine combining PADRE, 
polyriboinosinic:polyribocytidylic acid (poly(I:C)), a toll-
like receptor 3 ligand, and a minimal CTL (E749-57) epitope. 
In comparison to peptide with PADRE or Poly(I:C) alone, 
this combination elicited a high CD8+ T cell response and 
improved the therapeutic anti-tumor effects against TC-1 
tumor. Intratumoral administration with E7 peptide in com-
bination with PADRE and poly(I:C) generated better CD8+ T 
cell immune responses when compared with subcutaneous 
vaccination [123]. Combining a long CTL (E43-62) epitope 
with poly(I:C) and the vascular disrupting agent 5,6-
dimethylxanthenone-4-acetic acid (DMXAA), has also been 
shown to enhance the E7 specific CD8+ T cell immune re-
sponses. Interestingly, the timing/treatment regimen of 
DMXAA administration played an important role in vaccine 
efficacy [124]. The transmission of HPV-16 is mainly via the 
genital mucosal route, thus mucosal immune responses are 
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of interest when developing vaccination strategies against 
HPV. The therapeutic vaccine that co-delivered peptides 
from HPV-16 E744-62 and E643-57 proteins, along with the 
non-toxic mucosal adjuvant CT-2* generated strong sys-
temic and mucosal cellular immunity, along with anti-tumor 
efficacy [125].  
Human Trials of Immunotherapy for HPV Infection  
 Several peptide-based therapeutic HPV vaccines have 
been evaluated to be safe and well tolerated in early phase 
I/II clinical trials (Table 1) [105-107, 126]. In a phase I clini-
cal study, 12 patients with refractory cervical cancer were 
vaccinated with an E7-derived lipopeptide (HPV-16 E786-93)
linked to PADRE. After four vaccinations, neither adverse 
side effects nor clinical responses were observed in patients 
[126]. Phase I/II trials have also tested two HPV-16 peptides, 
E711-20 and E786-93, and a PADRE emulsion in the Montanide 
ISA 51 adjuvant in patients with recurrent or refractory cer-
vical cancer [105, 106]. This therapeutic vaccine showed no 
significant adverse effects in both trials. In the phase I study, 
2 out of 19 patients showed tumor-regression after chemo-
therapy following vaccination [105]. In the phase II trial, 2 
out of 15 patients had diseased states that were unchanged 
more than 1 year after vaccination [106]. Based on these 
studies, it was suggested that vaccination of patients with 
less advanced cervical disease might be more effective [105, 
106]. Therefore, a vaccine candidate in patients with earlier 
stages of HPV-induced disease was tested in a phase I trial 
[107]. A total of 18 patients with HPV-16-positive high-
grade CIN or vulvar intraepithelial neoplasia (VIN) were 
vaccinated with the HPV-16 E712-20 peptide in Montanide 
ISA 51 and the E786-93 lipopeptide linked to PADRE. None 
of the patients demonstrated a delayed type hypersensitivity 
(DTH) response. In this case, 3 of 18 patients were free of 
dysplasia after vaccination and 6 patients had partial remis-
sions. HPV E7-specific T cell immunity was detected in pe-
ripheral blood mononuclear cells from 10 out of 16 patients 
and an increased S100+ dendritic cell infiltrate was observed 
in 6 out of 6 patients tested. Overall, these peptide-based 
vaccines were more effective in women who had early stage 
cervical cancer than in women whose immune systems were 
compromised by progressive disease [107].  
 A strategy that enhances immune responses to peptide-
based vaccines by using a long overlapping peptides vaccine 
has been tested in early phase clinical trials. One such vac-
cine consisted of HPV E6 and E7 peptides (25-35 amino 
acids long with overlapped 10-14 amino acids) and was for-
mulated in Montanide ISA 51 adjuvant. This vaccine was 
evaluated in 43 patients with end-stage cervical cancer. The 
vaccine was well tolerated, and stimulated the production of 
IFN--associated T cell responses [101]. The same vaccine 
was used in a phase II trial with six patients with resected 
HPV-16 positive cervical cancer. This work also showed that 
this vaccine increased the activity and production of HPV-
16-specific CD4+ and CD8+ T cells in all six patients [102]. 
Furthermore, this vaccine was tested in a phase II trial in 20 
women with HPV-16-positive grade 3 VIN. The overlapping 
peptides vaccine elicited T cell responses and a complete 
clinical response in 9 out of 19 patients after the first 12 
months. These responses were maintained at 24 months fol-
low-up [103]. Overall, the overlapping long peptides vaccine 
offers a promising strategy for the treatment of women who 
are in earlier stages of HPV-induced disease. 
Table 1. Summary of Clinical Trials for Peptide-based Therapeutic HPC Vaccine Candidates 
Vaccine Composition/ 
Adjuvant 
Target  
Antigen(s) 
Phase Patients 
Immune  
Response 
Clinical Response Ref. 
E786-93 lipopetide linked to 
PADRE 
HPV-16 E7 I 
12 patients (HLA-A2-positive) with 
recurrent or persistent cervical cancer 
(HPV-16-positive) 
CTL response 
in 7 patients 
No clinical response [126] 
19 patients (HLA-A2-positive) with 
recurrent or residual cervical cancer 
(HPV-16-positive) 
2 stable disease;  
2 showed tumor-
regression after chemo-
therapy following vac-
cination 
[105] 
E711-20, E786-93 and PADRE 
emulsified in Montanide 
ISA 51 adjuvant 
HPV-16 E7 I/II 
15 patients (HLA-A2-positive) with 
recurrent or residual cervical cancer 
(HPV-16-positive) 
NO CTL re-
sponse 
2 stable disease [106] 
E712-20 in Montanide ISA 51 
and E786-93 lipopeptide 
linked to PADRE 
HPV-16 E7 I 
18 patients (HLA-A2-positive) with 
high grad CIN/VIN (HPV-16-positive) 
CTL response 
in 10 patients; 
No DTH 
3 complete responses; 
 6 partial responses 
[107] 
I 35 end-stage cervical cancer patients Not determined [101] 
II
6 patients with resected cervical cancer 
(HPV-16- positive) 
Not determined [102] 
Overlapping long peptide 
(nine E6 and four E7 pep-
tides of 25-35 amino acids 
long with an overlap of 10-
14 amino acids) emulsified 
in Montanide ISA 51 
HPV-16 
E6/E7 
II
20 patients with grade 3 VIN 
(HPV-16- positive) 
IFN- T cells 
induced 
9 complete responses; 
 6 partial responses 
[103] 
Abbreviations: PADRE: Pan HLA-DR epitope; HPV: Human papillomavirus; HLA: Human leukocyte antigen; CTL: Cytotoxic T lymphocyte; VIN: Vulvar intraepithelial neoplasia; 
DTH: Delayed type hypersensitivity; IFN: Interferon.
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CONCLUSION  
 Although commercial preventive or prophylactic HPV 
vaccines are now available and have the potential to prevent 
the onset of cervical cancer and other HPV-associated ma-
lignancies, it is predicted that it will take decades to signifi-
cantly reduce the prevalence of cervical cancer. Additionally, 
the full effect of the new prophylactic HPV vaccines on cer-
vical cancer incidence can only be evaluated decades after 
implementation. Thus, development in the meantime of a 
therapeutic HPV vaccine that is safe, economical, and effec-
tive is a priority.  
 The most promising therapeutic vaccine candidates are 
based on the generation of cell-mediated immune responses 
to eliminate HPV infection. Based on the present under-
standing of the molecular progression of cervical cancer, the 
E6 and E7 oncoproteins are the currently preferred targets 
for antigen-specific cellular immunity, since they are consti-
tutively expressed in virtually all cervical cancer cells and 
are essential for the induction and maintenance of HPV-
associated disease. Synthetic peptide-based vaccines have 
been extensively studied for the treatment of HPV infection 
owing to their safety, stability, and ease of production. How-
ever, many peptide-based vaccines had struggled with epi-
tope identification and poor immunogenicity. To address 
these problems, short and long peptides, containing CTL and 
HTL epitopes or with overlapping coverage of the complete 
E6 and/or E7 sequence, have been used to improve the effi-
cacy of peptide-based vaccines. Moreover, different catego-
ries of adjuvants and novel delivery systems were developed 
and employed for peptide-based vaccine design to enhance 
immunogenicity. A number of strategies for peptide anti-
HPV vaccine design have been evaluated in early-phase 
clinical trials, and encouraging results in preclinical animal 
studies illustrate the promise of such approaches. Perhaps the 
most promising strategies have involved the use of long pep-
tides (including CD4+ and CD8+ epitopes) or a combination 
of overlapping peptides with a variety of immunogenic de-
livery systems. However, further developments in delivery 
and adjuvant systems will be required to produce a therapeu-
tic anticancer peptide vaccine suitable for widespread use in 
humans. 
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ABBREVIATIONS  
APC = Antigen presenting cell 
CIN = Cervical intraepithelial neoplasia 
CRPV = Cottontail rabbit papillomavirus 
CTL = Cytotoxic T lymphocyte 
DC = Dendritic cell 
DMXAA = 5,6-Dimethylxanthenone-4-acetic acid 
DOTAP = 1,2-Dioleyoyl-3-trimethylammonium pro-
pane 
DTH = Delayed type hypersensitivity 
GM-CSF = Granulocyte-macrophage colony-
stimulating factor 
HLA = Human leukocyte antigen 
HPV = Human papillomavirus 
HTL = Helper T lymphocyte 
IFA = Incomplete Freund’s adjuvant 
IFN = Interferon 
IL = Interleukin 
IRF = Interferon regulatory factor 
LC = Langerhans cell 
LCP = Lipid core peptide 
LPD = Liposome-Protamin-DNA 
MHC = Major histocompatibility complex 
MPL = Monophosphoryl lipid A 
NK cell = Natural killer cell 
ODN-CpG = Oligodeoxynucleotides (ODN)-CpG 
PADRE = Pan HLA-DR epitope 
Pam2-KGG = Dipalmitoyl-lysine-glysine-glysine 
Poly(I:C) = Polyriboinosinic:polyribocytidylic acid 
pRb = Retinoblastoma 
Th cell = Helper T cell 
VIN = Vulvar intraepithelial neoplasia 
VLP = Virus-like particle 
VM = VacciMax
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Chapter Three	  
Synthesis of Polymer-peptide Conjugates and 
Epitope Selection  
 
 
“Self-adjuvanting polymer-peptide conjugates as therapeutic vaccine 
candidates against cervical cancer” 
 
Liu, T. Y.; Hussein, W. M.; Jia, Z.; Ziora, Z. M.; McMillan, N. A. J.; Monteiro, M. J.; Toth, I.; 
Skwarczynski, M., Self-adjuvanting polymer-peptide conjugates as therapeutic vaccine candidates 
against cervical cancer. Biomacromolecules, 2013, 14, 2798-2806. 
 
 
3.1 Introduction to this publication 
This chapter was published as an original article in Biomacromolecules. In this article, the synthesis 
of peptide epitope candidates, the optimal synthetic pathway for the production of polymer-peptide 
conjugates, and in vivo tumor treatment experiments were investigated. The lead polymer-peptide 
construct with micrometer particle size was able to generate therapeutic effect against HPV E7-
positive tumor cells without the help of any adjuvant.  
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ABSTRACT: Dendrimers are structurally well-deﬁned, syn-
thetic polymers with sizes and physicochemical properties
often resembling those of biomacromolecules (e.g., proteins).
As a result, they are promising candidates for peptide-based
vaccine delivery platforms. Herein, we established a synthetic
pathway to conjugate a human papillomavirus (HPV) E7
protein-derived peptide antigen to a star-polymer to create a
macromolecular vaccine candidate to treat HPV-related
cancers. These conjugates were able to reduce tumor growth
and eradicate E7-expressing TC-1 tumors in mice after a single immunization, without the help of any external adjuvant.
■ INTRODUCTION
Vaccination is one of the most cost-eﬀective public health
interventions, and has been proposed as a promising strategy
for the treatment of cancer.1 Cervical cancer results from the
infection of the cervix with human papillomavirus (mainly HPV
type 16), which disrupts the cell cycle through interaction
between HPV proteins and the host cell.2 Prophylactic vaccines
against HPV have been developed to prevent HPV infection
(and by extension, cervical cancer), achieving the best results if
administered prior to the commencement of sexual activity.3
However, a large proportion of the global population is already
infected, and many women will continue to become infected
with cervical cancer-associated HPV strains until global vaccine
coverage is achieved.4,5 Furthermore, the long-term eﬃcacy of
the new HPV vaccines can only be evaluated decades after
implementing the existing prophylactic vaccination.6 Impor-
tantly, prophylactic vaccines protect the host against viral
infection but are not designed to kill tumor cells. These
limitations have prompted research into the development of
therapeutic vaccines that treat HPV-related cancer.2,7−11
Therapeutic vaccine candidates against HPV-related cancers
were usually designed to elicit a cytotoxic T-cell response by
targeting E7 oncoprotein. This protein is constitutively
expressed in cancer cells and is required for the induction
and maintenance of tumor growth. T-cells recognize tumor-
associated antigen in the form of a deﬁned short peptide
sequence (T cell epitope), rapidly and speciﬁcally killing target
cells that display the antigen.12 This approach to treating cancer
overcomes the many disadvantages of classical chemotherapy,
and other therapies like siRNA, which is severely limited by the
instability and poor delivery of siRNA molecules into the
targeted cells. Therapeutic vaccines use the body’s natural
ﬁghting system, and have minimal risk of side eﬀects.
All reported peptide-based therapeutic HPV vaccine
candidates required formulation with an adjuvant (immunos-
timulant) to produce the desired immune response.2 Not only
are there a limited number of adjuvants approved for human
use, but many of these adjuvants are associated with toxicity
and low eﬃcacy.13 Therefore, the discovery and development
of novel adjuvants with potent immunomodulatory activities is
of signiﬁcant importance in the ﬁeld of cancer immunotherapy.
Speciﬁcally, the development of potent and well-deﬁned
adjuvants without adverse toxicity is crucial to the success of
therapeutic vaccines.14
Dendrimers are structurally well-deﬁned, synthetic polymers
that can be designed to mimic the size and physiochemical
properties of biomolecules (e.g., proteins).15 Their hyper-
branched structure allows the attachment and presentation of
antigen molecules at the periphery of the dendrimer, resulting
in a highly multifunctional biomacromolecule.15 It was
demonstrated that a Multiple Antigenic Peptide (MAP) system
with a poly lysine core16 was able to generate high antibody
titers as a prophylactic vaccine, but only when coadministered
with an adjuvant. Similarly, linear polymers with the peptide
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epitopes randomly conjugated along the polymer backbone also
generated antibody responses when coadministered with the
toxic complete Freund’s adjuvant (CFA).17 To overcome these
disadvantages, well-deﬁned polymer-based amphiphiles were
proposed. Polyacrylate was selected as the most promising
candidate because poly(acrylic acid), and its esters were easy to
synthesize and had little or no toxicity.18,19 We recently
reported the ability of polyacrylate amphiphilic dendrimers
(decorated with B-cell epitopes on the dendrimer’s periphery)
to act as a self-adjuvanting prophylactic vaccine, and induced a
protective (humoral) immunity.20,21 However, while there are a
substantial number of self-adjuvanting systems and adjuvants
that induce humoral immunity, the induction of cellular
responses for therapeutic vaccination is more challenging. For
example, aluminum salts, the only adjuvant that is widely used
in humans, are recognized to essentially only stimulate a
humoral immunity.22,23 Thus, there is an urgent need for
alternatives that are able to induce cellular immune responses.
In this work, we hypothesized that a star polymer-based
delivery systems might have the adjuvanting potency to
generate T-cell mediated immunity against cells that produce
the E7 protein, and thus could eradicate tumor cells. We
designed and synthesized polymer−peptide conjugates with the
well-known HPV-16 E7 protein epitope 8Q (QAEPDRAHY-
NIVTFCCKCD; E744−62), which contains a CTL epitope
(CD8+ cytotoxic T lymphocytes), and T-helper cell (CD4+)
and B-cell epitopes (Figure 1).9 This combination makes 8Q an
ideal candidate to stimulate long-term vaccine eﬃcacy to kill
cancer cells. We designed a short series of modiﬁed epitopes
(Figure 1) to avoid uncontrolled aggregation of the cysteine-
rich 8Q epitope. These epitopes were conjugated to the
dendritic structure that resembled a four-arm star-polymer
P(tBA37-)4 (S4) and self-assembled into particles under
aqueous conditions. All conjugates produced microparticles
when formulated in phosphate buﬀer saline (PBS). A conjugate
that contained the 8Qmin epitope was able to reduce tumor
growth and eradicate E7-expressing TC-1 tumors in mice after
a single immunization, without help from any external adjuvant.
■ EXPERIMENTAL SECTION
Materials. Protected L-amino acids were purchased from
Novabiochem (Merck Chemicals, Darmstadt, Germany) and Mim-
otopes (Melbourne, Australia). pMBHA resin was purchased from
Peptides International (Kentucky, USA). Rink amide MBHA resin,
N,N′-dimethylformamide (DMF), dichloromethane (DCM), meth-
anol, N,N′-diisopropylethylamine (DIPEA), piperidine and triﬂuoro-
acetic acid (TFA) were obtained from Merck (Hohenbrunn,
Germany). Cu wires were purchased from Aldrich (Steinheim,
Germany). t-Butyl acrylate (tBA, Aldrich, > 99%) was deinhibited
before use by passing through a basic alumina column, ethyl 2-
bromoisobutyrate (EBiB, Aldrich, 98%), tripropargylamine (TPA,
Aldrich, 98%), dimethyl sulfoxide (DMSO, Labscan, AR grade),
N,N,N′,N′,N″-pentamethyldiethylenetri-amine (PMDETA, Aldrich,
99%), copper(I) bromide (Cu(I)Br, MV Laboratories, Inc.,
99.999%), copper(II) bromide (CuBr2, Aldrich, 99%) were used as
received. Propargyl nitroxide was synthesized according the previous
procedure.24 1-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexaﬂuorophosphate (HBTU) and 2-(1H-7-azabenzotriazol-1-yl-
1,1,3,3-tetramethyl uronium hexaﬂuorophosphate methanaminium
(HATU) were purchased from Mimotopes (Melbourne, Australia).
HPLC grade acetonitrile was obtained from Labscan (Bangkok,
Thailand). All other reagents were obtained at the highest available
purity from Sigma-Aldrich (Castle Hill, NSW, Australia).
Microwave-assisted Boc-SPPS was carried out using a SPS mode
CEM Discovery reactor (CEM Corporation, Matthews, NC, USA).
Anhydrous hydroﬂuoric acid (HF) was supplied by BOC gases
(Sydney, NSW, Australia). A Kel-F HF apparatus (Peptide Institute,
Osaka, Japan) was used for HF cleavage. Electrospray ionization mass
spectrometry (ESI-MS) was performed using a Perkin-Elmer-Sciex
API3000 instrument with Analyst 1.4 software (Applied Biosystems/
MDS Sciex, Toronto, Canada). 1H nuclear magnetic resonance (1H
NMR) spectra were recorded with a Bruker Avance 300 MHz
spectrometer (Bruker Biospin, Germany). Analytical reversed-phase
high-performance liquid chromatography (RP-HPLC) was performed
using an Agilent instrument with a 1 mL/min ﬂow rate and detection
at 214 nm. Separation was achieved using a 0−100% linear gradient of
solvent B over 40 min with 0.1% TFA/H2O as solvent A and 90%
MeCN/0.1% TFA/H2O as solvent B on either a Vydac analytical C4
column (214TP54; 5 μm, 4.6 mm × 250 mm) or a Vydac analytical
C18 column (218TP54; 5 μm, 4.6 mm × 250 mm). Preparative RP-
HPLC was performed on Shimadzu (Kyoto, Japan) instrumentation
(either LC-20AT, SIL-10A, CBM-20A, SPD-20AV, FRC-10A or LC-
20AP x 2, CBM-20A, SPD-20A, FRC-10A) in linear gradient mode
using a 10−20 mL/min ﬂow rate, with detection at 230 nm.
Separations were performed with solvent A and solvent B on either a
Vydac preparative C4 column (214TP1022; 10 μm, 22 mm × 250
mm) or a Vydac preparative C18 column (218TP1022; 10 μm, 22 mm
× 250 mm). Particle size was measured by dynamic light scattering
(DLS) using a Malvern Zetasizer Nano Series with DTS software.
Sizes were analyzed using a noninvasive backscatter system. Multi-
plicate measurements were performed at 25 °C with scattering angle of
173° using disposable cuvettes and the number-average hydrodynamic
particle diameter are reported. The average particle diameter in PBS
was determined with a ZEISS LSM 510 META confocal microscope.
The software used for image acquisition was AIM 4.2 (Carl Zeiss,
Ltd.) and Carl Zeiss Zen 2009 was used for image analysis.
Synthesis of 8Q Peptide. 8Q epitope (QAEPDRAHY-
NIVTFCCKCD; E744−62) was synthesized on pMBHA resin
(substitution ratio: 0.45 mmol/g, 0.2 mmol scale, 0.44g) using
HBTU/DIPEA Boc-chemistry by Microwave-Assisted Solid-Phase
Peptide Synthesis (MW-SPPS). The temperature was set at 70 °C
(at 20 W, 10 min) for amino acid coupling except for His, Cys and
Asp, which were coupled at 50 °C (at 20 W, 15 min). Each amino acid
coupling cycle consisted of Boc-deprotection with neat TFA (2 × 1
min, at room temperature (RT)), a 1 min DMF ﬂow wash, followed
by 10 min coupling with the preactivated amino acid. Amino acid
activation was achieved by dissolving Boc-amino acid (0.84 mmol, 4.2
equiv), in a 0.5 M HBTU/DMF solution (1.6 mL, 0.8 mmol, 4.0
equiv) followed by the addition of DIPEA (0.22 mL, 1.24 mmol, 6.2
equiv). Amino acids were preactivated for 1 min prior to their addition
to the resin. For peptides containing His(DNP) residues, the DNP
(2,4-dinitrophenyl) group was cleaved by treating the resin with 20%
(v/v) β-mercaptoethanol and 10% (v/v) DIPEA in DMF for 2 × 1 h
treatments prior to peptide cleavage. Upon completion of synthesis
and removal of the dinitrophenyl (DNP) protecting group, the resin
was washed with DMF, DCM, and MeOH, then dried (vacuum
desiccator). The peptide was cleaved from the resin using HF, with p-
Figure 1. The amino acid sequence of the original 8Q epitope and its
novel derivatives. The CTL epitope (CD8+ cytotoxic T lymphocytes),
T-helper cell (CD4+), and B-cell epitope are highlighted within the 8Q
sequence. The immunologically redundant pentapeptide sequence is
indicated by italic font.
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cresol and p-thiocresol as scavengers. The cleaved peptide was
precipitated, ﬁltered, and washed thoroughly with ice-cold Et2O and
dissolved in 50% MeCN/0.1% TFA/H2O. After lyophilization, the
crude peptide was obtained as an amorphous powder. The product
was puriﬁed by preparative RP-HPLC on a C18 column with a solvent
gradient of 0−50% solvent B over 50 min. HPLC analysis (C18
column): tR = 19.18 min, purity >95%. Yield: 12%, ESI-MS: m/z
2213.2 (calc 2213.5) [M+H]+; 1107.7 (calc 1107.2) [M+2H]2+; 738.5
(calc 738.5) [M+3H]3+; MW 2212.49.
Synthesis of Azidoacetic Acid (N3CH2CO2H). Azidoacetic acid
was synthesized using a similar method to published procedure.25
Sodium azide (6.0 g, 92.3 mmol, 3.0 equiv) was dissolved in H2O (10
mL), and bromoacetic acid (4.3 g, 30.8 mmol, 1.0 equiv) was added.
The reaction was stirred continuously in an ice bath for 24 h and
subsequently acidiﬁed with 32% HCl (10 mL). The product was then
extracted with Et2O (4 × 50 mL), dried over anhydrous MgSO4 and
the solvent was evaporated under vacuum. The ﬁnal product was
obtained as a colorless oil (2.95 g, 95%) after prolonged evaporation
under vacuum to remove organic solvent and the last traces of water.
1H NMR (300 MHz, CDCl3) δ 10.60 (br s, 1H, OH), 3.98 (s, 2H,
CH2).
13C NMR (100 MHz, CDCl3) δ 50.0, 173.7.
Synthesis of Boc-Thr(Fmoc-Val)−OH. The isopeptide unit was
synthesized according to a published procedure.26−28
Synthesis of 1,3-di(hydroxymethyl)-5-(prop-2-ynyloxy)-
benzene. This compound was prepared as previously described.29,30
1H NMR (300 MHz, CD3OD): δ 2.52 (t, J = 2.4 Hz, 1H, CH2C
CH), 4.68 (bs, 4H, 2xCH2OH), 4.71 (d, J = 2.4 Hz, 2H, CH2C
CH), 6.92 (bs, 2H, ArH), 7.00−6.98 (m, 1H, ArH).
Synthesis of Polyacrylate P(tBA37-)4. The alkyne-function-
alized 4-arm poly(t-butyl acrylate) star (S4) was synthesized by atom-
transfer radical polymerization. Star-polymer P(tBA37-Br)4
21 (Mn =
14900, polydispersity index (PDI) = 1.05; 0.700 g, 3.68 × 10−5 mol),
propargyl nitroxide (0.078 g, 3.72 × 10−4 mol), and PMDETA (0.043
g, 2.48 × 10−4 mol) were dissolved in 6 mL of DMSO/toluene mixture
(1:2, vol). The mixture was purged with argon for 20 min before the
addition of CuBr (0.033 g, 2.32 × 10−4 mol). The reaction was stirred
at RT for 30 min, then diluted by THF and passed through an
activated basic alumina column. The solution was concentrated and
the polymer was recovered by precipitation into a MeOH/water
(50:50 vol) mixture and then ﬁltered. The polymer was further
puriﬁed by preparative gel permeation chromatography (GPC). GPC:
Mn = 15730, PDI = 1.06.
1H NMR (CDCl3): δ 1.11−1.21 (m, 15H,
methyl group of core and TEMPO ring), 1.45 (b, methyl protons of t-
BA repeat units), 1.81, 2.21 (b, methylene and methine protons of
polymer backbone), 2.40 (s, 4H, (−OCH2-CCH)4), 3.76, (b, 4H,
methine proton on a TEMPO ring), 3.80−4.25, (b, 20H, (methylene
protons of the core, methine proton of t-BA unit close to the
alkoxyamine linkage, methylene protons of propargyl group).
Synthesis of N-Terminus Model Azide. N-terminus model azide
(N3CH2CO-Phe-Cys-NH2) was synthesized by manual stepwise SPPS
on rink amide MBHA resin (substitution ratio: 0.59 mmol/g, 0.2
mmol scale, 0.34 g) using HBTU/DIPEA Fmoc-chemistry. Amino
acid activation was achieved by dissolving Fmoc-amino acid (0.84
mmol, 4.2 equiv), in 0.5 M HBTU/DMF solution (1.6 mL, 0.8 mmol,
4.0 equiv) followed by the addition of DIPEA (146 μL, 0.84 mmol, 4.2
equiv). Coupling cycle consisted of Fmoc deprotection with 20% of
piperidine in DMF (twice, 10 and 20 min), a 1 min DMF ﬂow-wash,
followed by coupling with 4.2 equiv of preactivated Fmoc-amino acids
(2 × 2 h). The attachment of azidoacetic acid (4.2 equiv) was achieved
using HBTU (3 equiv)/DIPEA (4.2 equiv) at room temperature (2 ×
2 h). Upon completion of synthesis, the resin was washed with DMF,
DCM, and MeOH, then dried (vacuum desiccator). The cleavage of
model azide was carried out by stirring the resin in the solution of TFA
(99%)/triisopropylsilane/water (95:2.5:2.5) for 4 h. The cleaved
peptide was precipitated, ﬁltered, and washed with ice-cold Et2O. After
lyophilization the crude peptide was obtained as an amorphous
powder. The product was puriﬁed by preparative RP-HPLC on C18
column with solvent gradient 0−50% solvent B over 50 min. HPLC
analysis (C18 column): tR = 18.4 min, purity >95%. Yield: 96% ESI-
MS: m/z 702.1 (calc 701.8) [2M+H]+; 351.7 (calc 351.4) [M+H]+;
MW 350.40.
Synthesis of N-Terminus 8Q Azide. 8Q azide peptide epitope
(N3CH2CO-QAEPDRAHYNIVTFCCKCD-NH2) was synthesized
according to the above procedure. Fmoc deprotection of Thr, Val
and Ile were performed with 2% of 1,8-Diazabicycloundec-7-ene
(DBU) in DMF (twice, 5 and 10 min) instead of 20% piperidine in
DMF. HPLC analysis (C18 column): tR = 17.5 min, purity >95%.
Yield: 17%. ESI-MS: m/z 1148.8 (calc 1148.8) [M+2H]2+; 766.2 (calc
766.2) [M+3H]3+; MW 2295.54.
Synthesis of N-Terminus 8Qmin Azide. 8Qmin azide peptide
epitope (N3CH2CO-QAEPDRAHYNIVTF-NH2) was synthesized
according to the above procedure. Fmoc deprotection of Thr, Val,
and Ile was performed with 2% DBU in DMF (twice, 5 and 10 min)
instead of 20% piperidine in DMF. HPLC analysis (C18 column): tR =
18.3 min, purity >95% (Figure S1). Yield: 42%. ESI-MS: m/z 1743.3
(calc 1743.8) [M+H]+; 872.3 (calc 872.4) [M+2H]2+; MW 1742.85.
Synthesis of N-Terminus 8QSer Azide. Method A. 8QSer azide
peptide epitope (N3CH2CO-QAEPDRAHYNIVTFSSKSD-NH2) was
synthesized according to the above procedure. Fmoc deprotection of
Thr, Val, and Ile were performed with 2% DBU in DMF (twice, 5 and
10 min) instead of 20% piperidine in DMF. HPLC analysis (C18
column): tR = 16.66 min, purity >95%. Yield: 14%. ESI-MS: m/z
1124.8 (calc 1124.7) [M+2H]2+; 750.2 (calc 750.1) [M+3H]3+; MW
2247.34.
Method B. The isopeptide 8QSer azide peptide epitope was
synthesized according to the above procedure. Boc-Thr(Fmoc-Val)−
OH was used to introduce Thr and Val. Fmoc deprotection were
performed only with 20% piperidine in DMF (twice, 10 and 20 min).
Isopeptide 8QSer azide was cleaved from resin (tR = 15.82 min, C18),
lyophilized, and dissolved in 50% aqueous MeCN. Ammonia solution
(25%) was added dropwise until the pH was 8−9. The reaction
mixture was stirred for 2 h to form the desired migrated 8QSer azide.
HPLC analysis (C18 column): tR = 16.66 min, purity >95% (Figure
S1). Yield: 55%. ESI-MS: m/z 1124.8 (calc 1124.7) [M+2H]2+; 750.2
(calc 750.1) [M+3H]3+; MW 2247.34.
Synthesis of N-Terminus 8QLys Azide. 8QLys azide peptide
epitope (N3CH2CO-QAEPDRAHYNIVTFSKKKK-NH2) was synthe-
sized according to the above procedure. Fmoc deprotection of Thr,
Val, and Ile were performed with 2% DBU in DMF (twice, 5 and 10
min) instead of 20% piperidine in DMF. HPLC analysis (C18
column): tR = 15.9 min, purity >95% (Figure S1). Yield: 18% ESI-MS:
m/z 1172.3 (calc 1172.3) [M+2H]2+; 781.9 (calc 781.9) [M+3H]3+;
586.9 (calc 586.6) [M+4H]4+; 469.8 (calc 469.5) [M+5H]5+; MW
2342.61.
Copper-Catalyzed Alkyne−Azide Cycloaddition (CuAAC)
Reaction: Model Studies. To determine the optimal conditions to
avoid disulﬁde formation during the CuAAC reaction, model azide and
1,3-di(hydroxymethyl)-5-(prop-2-ynyloxy)benzene were employed.
The reactions were conducted by using diﬀerent copper sources (Cu
wires, CuSO4, CuI), with or without adding reducing agent (ascorbic
acid, tris(2-carboxyethyl)phosphine), diﬀerent solvents (solvent B
(90% MeCN/0.1% TFAH2O), DMF), and stirring at 50 °C or room
temperature. Brieﬂy, model azide (1 equiv) and 1,3-di-
(hydroxymethyl)-5-(prop-2-ynyloxy)benzene (1 equiv) were dissolved
in DMF (1 mL), and the copper source added. The air in the reaction
mixture was removed either by nitrogen or argon bubbling. The
reaction mixture was covered and protected from light with aluminum
foil and stirred at either 50 °C or room temperature under nitrogen or
argon atmosphere. During the reaction, samples (30 μL) were
frequently taken and analyzed by analytical HPLC and ESI-MS to
monitor the progress of reaction.
Synthesis of Vaccine Candidate P(tBA37-)4-8Qmin (S4−
8Qmin). 8Qmin azide peptide epitope (1.8 mg, 1 μmmol, 10 equiv)
and P(tBA37-)4 (1.9 mg, 0.10 μmol, 1.0 equiv) were dissolved in
DMF (1 mL). Copper wires (60 mg)treated with concentrated
sulphuric acid (3 min), subsequently washed with distilled water,
methanol, and dried under reduced pressurewere added into the
mixture. The mixture was bubbled with nitrogen to remove the air.
The reaction mixtures were covered and protected from light with
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aluminum foil and stirred at 50 °C in a temperature controlled oil bath
under nitrogen atmosphere for 8 h. The wires were ﬁltered oﬀ from
the warm solution and washed with 1 mL of DMF. Millipore
endotoxin-free water (7 mL) was slowly added to the solution (0.005
mL/min). Particles formed through the self-assembly process were
exhaustively dialyzed against endotoxin-free water (pH = 6.8) using
presoaked and rinsed dialysis bags (Pierce Snakeskin, MWCO 3K).
The resulting particles were self-assembled into particles with
diameters above 1 μm as observed by dynamic light scattering.
Synthesis of Vaccine Candidate P(tBA37-)4-8QSer (S4−
8QSer). S4−8QSer was synthesized in the same manner as above.
8QSer azide peptide epitope (2.5 mg, 1 μmmol, 10 equiv) and star-
polymer p(tBA37-)4 (1.9 mg, 0.10 μmmol, 1.0 equiv) were dissolved
in DMF (1 mL). The reaction was terminated after 12 h. The resulting
particles were self-assembled into to yield diameters of around 150 and
700 nm as observed by dynamic light scattering.
Synthesis of Vaccine Candidate P(tBA37-)4-8QLys (S4−
8QLys). S4−8QLys was synthesized in the same manner as above.
8QLys azide peptide epitope (2.9 mg, 1 μmmol, 10 equiv) and star-
polymer p(tBA37-)4 (1.9 mg, 0.10 μmmol, 1.0 equiv) were dissolved
in DMF (1 mL). The reaction was terminated after 12 h. The resulting
particles were self-assembled into particles with a 26 nm diameter as
observed by dynamic light scattering.
Mice and Cell Lines. Female C57BL/6 (6−8 weeks old) mice
were used in this study and purchased from Animal Resources Centre
(Perth, Western Australia). TC-1 cells (murine C57BL/6 lung
epithelial cells transformed with HPV-16 E6/E7 and ras oncogenes)
were obtained from TC Wu.31 TC-1 cells were cultured and
maintained at 37 °C/5% CO2 in RPMI 1640 medium (Gibco)
supplemented with 10% heat inactivated fetal bovine serum (Gibco)
and 1% nonessential amino acid (Sigma-Aldrich). The animal
experiments were approved by the University of Queensland Animal
Ethics committee (DI/034/11/NHMRC) in accordance with National
Health and Medical research Council (NHMRC) of Australia
guidelines.
In Vivo Tumor Treatment Experiments. To test the eﬃcacy of
polymer−peptide conjugates as a therapeutic vaccine against
established tumors, groups of C57BL/6 mice (5 per group) were
ﬁrst challenged subcutaneously in the right ﬂank with 1 × 105/mouse
of TC-1 tumor cells. On the third day after tumor challenge, the mice
were injected subcutaneously at the tail base with 100 μg of polymer−
peptide conjugates in a total volume of 100 μL of sterile-ﬁltered PBS
or control formulations. Polymer-peptide conjugates consisted of S4−
8Qmin, S4−8Qser and S4−8QLys. Positive control received 30 μg of 8Q
emulsiﬁed in a total volume of 100 μL of Montanide ISA51 (Seppic,
France)/PBS (1:1, v/v). Three negative control groups were
administered PBS, 70 μg of 4-arm star-polymer alone (S4), or 4-arm
star-polymer (70 μg) + 8Q (30 μg) physical mixture (S4 + 8Q) in
total volume of 100 μL PBS. The mice were given a single
immunization only. The size of the tumor was measured by palpation
and calipers every two days and reported as the average tumor size
across the group of ﬁve mice or as tumor size in individual mice.32,33
Tumor volume was calculated using the formula V (cm3) = 3.14 ×
[largest diameter × (perpendicular diameter)2]/6.33 The mice were
euthanized when tumor reached 1 cm3 or started bleeding to avoid
unnecessary suﬀering.
Statistical Analysis. All data were analyzed using GraphPad Prism
5 software. Kaplan−Meier survival curves for tumor treatment
experiments were applied. Diﬀerences in survival treatments were
determined using the log-rank (Mantel-Cox) test, with p < 0.05
considered statistically signiﬁcant.
■ RESULTS AND DISCUSSION
Synthesis and Characterization of the Polymer−
Peptide Conjugates. Copper-catalyzed alkyne−azide 1,3-
dipolar cycloaddition (CuAAC) “click” reaction34 was used to
synthesize vaccine candidates against HPV-associated cancers.
These candidates possessed a hydrophobic polymeric core and
multiple copies of a peptide epitope derived from the HPV-16
E7 oncoprotein. The 8Q epitope and its new analogues were
applied as antigens, while the polyacrylate 4-arm star-polymer
served as a delivery platform. All the peptides contained CTL,
T-helper, and B-cell epitopes.
First, the alkyne-functionalized 4-arm poly(t-butyl acrylate)
star (S4) was synthesized by atom-transfer radical polymer-
ization (ATRP) and end-group functionalization with a very
narrow molecular-weight distribution (polydispersity index of
less than 1.06). 8Q epitope and its azide (N3CH2CO-
QAEPDRAHYNIVTFCCKCD-NH2) were synthesized using
microwave-assisted Boc- and Fmoc-SPPS, respectively. During
the initial synthesis, a so-called “diﬃcult” sequence35−37 inside
8Q epitope was identiﬁed to be composed of β-branched
amino acids (the IVT tripeptide). It was reported that the
presence of these sequences predisposed the peptide to
aggregate on the resin via β-sheet formation and inhibited
completion of Fmoc group deprotection.38,35 Indeed, a
signiﬁcant amount of amino acid deletion products were
detected during 8Q synthesis, resulting from incomplete
deprotection of the Fmoc group. Complete deprotection was
achieved by replacing piperidine with DBU for the removal of
Fmoc groups after coupling isoleucine, valine, and threonine.
To examine the “click” reaction, simple model compounds
were designed, in which an alkyne (1) and a dipeptide azide
possessing single thiol functionality (2) were coupled using
copper-wires as the catalyst (Scheme 1).21,39−41 Analysis of the
reaction showed that instead of the desired “click” product 3, a
disulﬁde bond-mediated dimer of 2 was exclusively produced.
Scheme 1. The CuAAC Reaction Was Examined Using the Model Compounds 1 and 2
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Subsequently, this dimer reacted with alkyne 1 producing
disulﬁde bond-mediated dimer of compound 3 (Figure S2).
Thus, formation of the single product could not be expected
during conjugation of S4 core with 8Q peptide which possessed
multiple thiol groups. In an eﬀort to eliminate disulﬁde bond
formation, we investigated alternative CuAAC “click” reaction
conditions by changing the copper source (copper wire, copper
sulfate, copper iodide), reducing agents (ascorbic acid, tris(2-
carboxyethyl)phosphine), solvents (DMF, acetonitrile/water/
triﬂuoroacetic acid, 90/10/0.1) and temperature (50 °C, RT).
Regardless of the experimental conditions, we were unable to
obtain compound 3 (Figure S3).
These observations prompted us to modify the 8Q peptide.
Three new epitopes were designed (Figure 1): 8Qmin
(QAEPDRAHYNIVTF), which lacked the CCKCD sequence;
8QSer (QAEPDRAHYNIVTFSSKSD), where the cysteine
moieties were replaced with their structural analog, serine;
and 8QLys (QAEPDRAHYNIVTFSKKKK), in which the whole
hydrophilic pentapeptide CCKCD was replaced with an
SKKKK sequence derived from a “solubilizing moiety”
incorporated in Pam2Cys/Pam3Cys-based vaccine candidates.
Pam2Cys/Pam3Cys are popular adjuvants used to stimulate an
immune response in peptide-based vaccines.15
8Qmin was conjugated to four-arm star-polymer to produce
S4−8Qmin (Scheme 2). The product, S4−8Qmin, was self-
assembled into particles via the solvent replacement method
(DMF/water) followed by dialysis against water to remove the
organic solvent, excess of unreacted peptide, and copper.
Formation of the conjugate was conﬁrmed by elemental
analysis,21 which showed a signiﬁcant increase in the nitrogen/
carbon ratio (N/C = 0.085) compared with that of S4 (N/C =
0.004), due to presence of a nitrogen-rich peptide. A high
conjugation eﬃcacy was obtained (3.5 peptide epitopes per
polymer, 88% substitution). The substitution ratio was
calculated based on comparison of the observed and theoretical
N/C ratio. DLS analysis showed that only large particles with
diameters over 1 μm were formed (Figure S4).
8QSer and 8QLys azide derivatives were synthesized using the
method developed for synthesis of the 8Q epitope. Despite the
use of DBU for removal of the protective Fmoc group, 8QSer
azide was obtained in relatively poor yield after tedious
puriﬁcation. The isopeptide method developed by Kiso and co-
workers was previously applied to the synthesis of peptides
containing a “diﬃcult” sequence.42−45 Thus, isodipeptide unit
(Boc-Thr(Fmoc-Val)−OH) was synthesized in a similar
manner to the reported procedure,26−28 and applied to the
synthesis of 8QSer azide (Scheme S1) to avoid aggregation of
the peptide during SPPS.44 The ﬁnal compound was obtained
after O−N acyl migration of the O-acyl isoform, with
signiﬁcantly improved purity and yield (Figure 2). Both
epitopes (8QSer and 8QLys) were coupled to S4 to produce
the desired conjugates (Scheme 2). The coupling for S4−8QSer
and S4−8QLys was calculated to be (on average) 3.0 (75%) and
3.0 (74%) epitopes per S4, respectively. Conjugation of
peptides to the polymer followed by self-assembly and dialysis
was repeated several times, producing virtually identical
products.
Both compounds (S4−8QSer and S4−8QLys) were self-
assembled in DMF/water and dialyzed against water. DLS
analysis indicated that S4−8QSer formed large nanoparticles (∼
530 nm; Figure S4). In contrast, the size distribution of S4−
8QLys particles was narrow, and smaller nanoparticles (26 nm)
were detected (Figure S4). To prepare samples for in vivo
experiments, S4−8Qmin, S4−8QSer, and S4−8QLys were
formulated in PBS. All of the conjugates formed a milky
suspension upon addition of the buﬀer (pH = 7.4). Confocal
images were used to visualize microparticles and their
aggregates (Figure S5). We were unable to quantitatively
determine particles size distribution using DLS, TEM, and
analytical ultracentrifugation.
In Vivo Tumor Treatment. To evaluate the therapeutic
eﬀect of polymer-peptide conjugates against established HPV
tumor using the newly designed epitopes, mice were immu-
nized on day 3 post-tumor implantation46,47 with S4−8Qmin,
Scheme 2. Synthesis of Polymer−Peptide Conjugates
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S4−8Qser, S4−8QLys or control groups (8Q emulsiﬁed with
IFA-like adjuvant (Montanide ISA51), physical mixture of S4
and 8Q, S4 alone, and PBS). Mice were monitored every 2 days
for evidence of tumor growth by palpation and calipers for 60
days.
The Kaplan−Meier survival curve (Figure 3a) showed that
100% of mice treated with physical mixture (S4 + 8Q), S4
alone and PBS were moribund (i.e., mice were sacriﬁced due to
tumor burden) by day 28, 33 and 33, respectively. In contrast,
the survival rate in the mice treated with S4−8Qmin, S4−8Qser
and 8Q + ISA51 was 60%, 20%, and 40% over two months,
respectively. Among the tested formulations, only S4−8Qmin
and positive control showed signiﬁcantly better survival
compared with tumor-bearing mice treated with negative
control (p < 0.0027).
As shown in Figure 3b, tumor-bearing mice treated with S4−
8Qmin showed slower tumor growth over time than the other
polymer-peptide conjugates and was similar to the mice treated
with positive control. Treatment with S4−8Qmin eradicated
tumor by day 21 post-tumor implantation in three mice, while
an initial tumor reduction was observed in remaining two mice
after 14−17 days (Figure 3c). It is noteworthy that an initial
reduction in tumor size was observed in four groups including
positive control and all conjugates (see Figure 3c and
Supporting Information, Figure S6a−c). Remission of tumor
growth was observed after 19 days, especially in the group
immunized with S4−8QLys. Thus, S4−8Qmin showed similar
eﬃcacy to the positive control while the antitumor eﬃcacy of
other conjugates was not statistically signiﬁcant. No adverse
side eﬀects or allergic responses were observed in mice
immunized with the conjugates, while one mouse from the
group immunized with an adjuvant (8Q + ISA51) developed an
adverse reaction (scratching resulting in patchy hair loss).
Chemical conjugation of epitopes with a polymer core was
essential to elicit a therapeutic eﬀect since S4 + 8Q failed to
induce an antitumor immune response. The three conjugates
(S4−8Qmin, S4−8Qser and S4−8QLys) demonstrated diﬀerent
antitumor activity, which might be associated with the ability of
antigen presenting cells to correctly process and display
diﬀerent epitopes. Correct antigen processing is essential to
trigger the desired cellular response. While 8Qmin is a native
fragment of the HPV-16 E7 protein, both 8QSer and 8QLys are
chemically altered epitopes where the CTL epitope is ﬂanked
with a foreign peptide on its C-terminal. This alteration might
impair antigen processing and consequently may have reduced
the cellular immune response.48−50 In addition, size can play
important role in immune responses, while some groups
reported that immune responses were signiﬁcantly stronger for
small nanoparticles (less than 100 nm),51,52 others claimed that
microparticles are required for strong activation of the immune
system.53,54 Small nanoparticles can easily migrate to lymphatic
nodes for antigen presentation, whereas large particles are
transported to lymphatic nodes by dendritic cells and the
immunity induced by large particles is often related to the
depot eﬀect.55 Interestingly, T-cell activation is often facilitated
by the extended presence of antigen through depot-forming
adjuvants.54 The three conjugates form microparticles and have
the tendency to aggregate further. This observation may
suggest that the diﬀerences in the conjugates antitumor activity
are not related to particle size.
Polymer−peptide conjugate S4−8Qmin demonstrated self-
adjuvanting activity because it induced a therapeutic eﬀect
against tumor cells without help of any external adjuvant. This
delivery system overcomes the poor immunogenicity of
peptide-based vaccines and the common toxic side eﬀects
associated with external adjuvants. Self-adjuvanting properties
of the polymer-based delivery system can be explained by
particle-attributed activation of the immune system.16,56,57
Particulate vaccines potentially cross-present the antigen, and
antigen cross-presentation is especially important to induce the
priming of the CD8+ T-cell immune responses that naturally
play a crucial role for therapeutic vaccines against cancer. This
delivery system also exploits the depot eﬀect (i.e., retaining the
antigen at the injection site), thus increasing the duration of
vaccine exposure to the immune cells. In addition, as particles
are covered by multiple copies of the same peptide antigen,
they should possess the advantages of a MAP system.
Furthermore, formulation of antigens into particles provides
some protection against enzymatic degradation, which is
important for highly susceptible peptide antigens. Noticeably,
in contrast to many previously reported peptide-based vaccine
candidates,33,46,47,58 S4−8Qmin demonstrated a therapeutic
eﬀect after a single immunization.
■ CONCLUSION
In conclusion, we established a synthetic pathway to produce
polymer-peptide conjugates as macromolecular vaccine candi-
dates against HPV-related cancers. The synthesis of peptide
epitopes was greatly improved by the change of standard SPPS
procedure and application of the isopeptide method.
Modiﬁcation of the immunogenic epitope allowed the
elimination of undesirable disulﬁde bond-based aggregation/
polymerization of the polymer-peptide conjugates.
Chemical alteration of 8Q epitope allowed us to ﬁnd the
most eﬀective epitope (8Qmin). Polyacrylate star-polymer
conjugated with this epitope produced a robust therapeutic
eﬀect against a tumor without the help of any external adjuvant.
This delivery system overcomes the poor immunogenicity of
peptide-based vaccines. In contrast to many previously reported
vaccine candidates, the conjugates demonstrated therapeutic
eﬀect after only a single immunization. Thus, we have
Figure 2. HPLC chart of crude 8QSer (a) synthesized by standard
SPPS and (b) O-acyl isopeptide methods.
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developed the ﬁrst self-adjuvanting delivery system for a
therapeutic peptide-based vaccine against cervical cancer.
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b) 
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Figure S1. HPLC trace of (a) 8Qmin azide peptide, (b) 8Qser azide peptide, and (c) 8QLys 
azide peptide. (Background signal was marked with a cross). 
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Figure S2. Model “click” reaction between alkyne 1 and azide 2 in DMF at 50 °C using 
copper wires as a Cu (I) source. The reaction progress was monitored by HPLC and the 
products were detected by MS. 
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 Cu source Reducing 
agent 
Solvent T °C Reaction 
time (h) 
Major product 
Cu wire  DMF 50 °C 20 h Dimer of 3 
Cu wire Asc-H
1 
DMF RT 28 h Dimer of 2 
CuSO4 Asc-H
1 
DMF RT 28 h Dimer of 2 
Cu wire  Solvent B
3 
RT 28 h Dimer of 2 
CuI Asc-H
1 
Solvent B
3 
RT 22 h Dimer of 2 
CuI Asc-H
1 
DMF RT 22 h Dimer of 2 
Cu wire Added TCEP
2
 
after 22 h 
DMF 50 °C 48 h Unidentified mixture 
CuSO4 Added TCEP
2
 
after 22 h 
DMF 50 °C 48 h Unidentified mixture 
1. Asc-H: ascorbic acid 
2. TCEP: tris(2-carboxyethyl)phosphine 
3. Solvent B: acetonitrile/water/trifluoroacetic acid, 90/10/0.1 
 
Figure S3. Summary of reaction conditions and results of CuAAC model studies. 
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a) 
 
 
b) 
 
 
c) 
 
 
Figure S4. Hydrodynamic diameter (volume-based particle size) as measured by DLS for (a) 
S4-8Qmin, (b) S4-8Qser, and (c) S4-8QLys in water. 
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Figure S5. Confocal microscope images of (a) S4-8Qmin, (b) S4-8Qser, and (c) S4-8QLys in 
PBS (scale bar: 20 µm). 
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Figure S6. Development of TC-1 tumor (up to 21 days) in five mice treated with (a) S4-
8Qser, (b) S4-8QLys, or (c) 8Q + ISA51. Female C57BL/6 (6-8 weeks old) mice were 
challenged with TC-1 tumor on day 0. The mice received vaccination on day three. 
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Scheme S1. Isopeptide method for the synthesis of peptides that contain a difficult sequence 
(8QSer). 
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4.1 Introduction to this publication 
This chapter was published in Current Drug Delivery as an original article. In this paper, the 
immunological properties of previously found lead vaccine candidate was evaluated. The ability of 
uptake of the conjugate by DCs and macrophages, and which subset of lymphocytes contributed 
mostly to the therapeutic immunity in our in vivo model were investigated. 
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Self-Adjuvanting Therapeutic Peptide-Based Vaccine Induce CD8+ Cyto-
toxic T Lymphocyte Responses in a Murine Human Papillomavirus Tumor 
Model 
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Abstract: Vaccine candidates for the treatment of human papillomavirus (HPV)-associated cancers are aimed to activate 
T-cells and induce development of cytotoxic anti-tumor specific responses. Peptide epitopes derived from HPV-16 E7 on-
cogenic protein have been identified as promising antigens for vaccine development. However, peptide-based antigens 
alone elicit poor cytotoxic T lymphocyte (CTL) responses and need to be formulated with an adjuvant (immunostimulant) 
to achieve the desired immune responses. We have reported the ability of polyacrylate 4-arm star-polymer (S4) conju-
gated with HPV-16 E744-57 (8Qmin) epitope to reduce and eradicate TC-1 tumor in the mouse model. Herein, we have stud-
ied the mechanism of induction of immune responses by this polymer-peptide conjugate and found prompt uptake of con-
jugate by antigen presenting cells, stimulating stronger CD8+ rather than CD4+ or NK cell responses  
Keywords: peptide subunit vaccine, human papillomavirus, therapeutic anticancer vaccine, star-polymer, polyacrylate, self-
adjuvanting, cytotoxic T lymphocyte (CTL) responses. 
INTRODUCTION 
 Human papillomavirus (HPV) is major cause of all cervi-
cal cancers with HPV type 16 (HPV-16) infection causing 
the majority of HPV-related cancers [1]. While prophylactic 
HPV vaccines have already been developed and commercial-
ized, they only protect the host against viral infection but 
have no therapeutic properties to eradicate established HPV 
infection. Thus, there is strong demand for development of 
therapeutic vaccines to eradicate HPV and control cervical 
cancer mortality. Such vaccines can provide a safe alterna-
tive to classical chemotherapy as they use the natural im-
mune system of our body to create a potent immune response 
against tumor cells. 
 Therapeutic HPV vaccine candidates are aimed to elicit 
cytotoxic T-cell responses and mainly focus on targeting 
HPV E7 oncogenic protein, as E7 protein is required for tu-
morigenesis and maintenance of tumor growth [1]. The 
whole oncoprotein cannot be used in vaccine formulation as 
it can induce genomic instability in normal human cells. 
However, peptide-based vaccines use only minimal non-
oncogenic epitopes necessary to stimulate immune re-
sponses. In general, peptides alone are non-immunogenic 
 
*Address correspondence to this author at the School of Chemistry and 
Molecular Biosciences, The University of Queensland, St Lucia, Queens-
land 4072, Australia; Tel: + 61 7 3346 9894; Fax: +61 7 3365 4273;  
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and the addition of an external adjuvant (immunostimulant) 
to induce the desired immune responses was required in all 
reported therapeutic peptide-based HPV vaccine approaches 
[1]. To date, only a limited number of adjuvants have been 
approved for human use and they are often toxic or their 
efficacy is low [2]. Thus, the development of new adjuvants 
or self-adjuvanting delivery systems with potent immuno-
modulatory properties and without adverse toxicity is of ma-
jor importance in the field of anti-cancer therapy [3, 4]. A 
large number of experimental adjuvants and self-adjuvanting 
systems are reported to induce humoral immune responses; 
however, triggering of cellular immunity against cancer cells 
is a particular challenge [5]. 
 Previously, we have demonstrated that the polyacrylate 
dendrimers conjugated to multiple copies of minimal B-cell 
epitope was able to induce humoral immunity without the 
use of an additional immunostimulant [6-8]. We also re-
ported that star polyacrylate-based vaccine delivery platform 
had the ability to reduce and eradicate tumor cells that pro-
duce the E7 oncoprotein in the mouse model. The lead vac-
cine candidate called S4-8Qmin possessing 8Qmin (E744-57, 
QAEPDRAHYNIVTF) epitope was able to shrink and eradi-
cate E7-expressing TC-1 tumors after a single-dose immuni-
zation in mice [9]. It has been proven that polymer-peptide 
conjugates can induce humoral immunity but the mode of the 
anti-cancer action of self-adjuvanting polymer-peptide con-
jugates has not been studied yet [10]. In this work, we have 
studied the mechanism of induction of immune responses by 
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these polymer-peptide conjugates. It was found that the con-
jugates were promptly taken up by antigen presenting cells 
including macrophages and dendritic cells (DCs). In addi-
tion, we had proven that CD8+ cytotoxic T lymphocytes 
(CTLs) played a major role in anti-tumor immunity upon 
administration of polymer-peptide conjugates.  
MATERIALS AND METHODS 
Synthesis of Vaccine Candidate P(tBA37-≡)4-8Qmin  
(S4-8Qmin) 
 Synthesis of polymer-peptide conjugates S4-8Qmin 
(Scheme 1) has been described in detail previously [9]. 
Briefly, the alkyne-functionalized poly(t-butyl) acrylate 
(P(tBA) 4-arm star-polymer (S4) was produced with the help 
of atom-transfer radical polymerization (ATRP) [11]. The 
8Qmin epitope ended with azide (N3CH2CO-QAEPDRAHY-
NIVTFCCKCD-NH2) was synthesized using Fmoc-SPPS 
and conjugated to the polyacrylate S4 via 1,3-dipolar copper-
catalyzed alkyne–azide cycloaddition (CuAAC) “click” reac-
tion [12] to produce S4-8Qmin. Then, the resulting S4-8Qmin 
conjugate formed particles via self-assembled process in a 
DMF/water mixture. The dialysis against endotoxin-free 
water (Millipore, Queensland, Australia) was performed to 
remove the excess of peptide, residual copper and DMF. 
Particle Size Measurement  
 The particle size and size distribution (span) of the con-
jugate was measured using the laser diffraction method 
(Mastersizer 2000, Malvern Instruments, UK) after formulat-
ing the conjugate in PBS. The geometrical diameter was pre-
sented as volume median diameter (D50%). The size distri-
bution (span) value of the formulation was defined by a 
standard formula: 
Span = (D90%-D10%)/D50% 
 D10%, D50% and D90% are the particle diameters for 
10th, 50th and 90th percentile of the undersized particle distri-
bution curve [13]. The size of particle of the conjugate was 
12 µm and size distribution was narrow (span < 1.2).  
Uptake of Conjugates by Dendritic Cells and Macro-
phages 
 An antigen presenting cells uptake assay was performed 
in a similar manner as described previously [14, 15]. Uptake 
of S4-8Qmin by DCs and macrophages was investigated using 
splenocytes marked with CD11c-A660 (eBioscience) and 
F4/80-APC-Cy7 (BioLegend, Pacific Heights Blvd, San Di-
ego, CA, USA) antibodies for DCs and macrophages, respec-
tively. Spleen was passed through stainless steel mesh to 
produce single-cell suspensions. Erythrocytes were lysed by 
erylysis buffer (Sigma-Aldrich) and the remaining cell popu-
lation was placed in a 6-well plate at a density of 2 x 105 
cells/well in phenol free IMDM Glutamax medium (Gibco®, 
Life Technologies), supplemented with 10% FBS, 50 µM 2-
mercaptoethanol (Gibco®, Life Technologies), 100 U/ml 
penicillin, and 100 µg/ml streptomycin (Gibco®, Life Tech-
nologies). The S4-8Qmin was labeled with Dil (1,1’ dioctade-
cyl-3,3,3’,3’tetramethylindocarbocyanine perchlorate) (Vy-
brant®, Life Technologies) by adding 0.5 µl of Dil to 100 µl 
of S4-8Qmin in PBS and incubating for 30 min (Dil rapidly 
adsorbs to the S4-8Qmin). Dil-labeled S4-8Qmin or Dextran-
FITC (positive control) were added to the wells and incu-
bated overnight. The adherent cells were scraped from the 
plate and incubated with Fc-block for 30 min at 4oC, centri-
fuged and re-suspended in buffer containing CD11c-A660 
and F4/80-APC-Cy7 antibodies for 30 min at 4°C. The cells 
were then centrifuged and re-suspended in 0.5 mL of FACS 
buffer (PBS, 0.02% sodium azide, 0.5% BSA) and analyzed 
using an LSR II flow cytometer (BD Biosciences). The fluo-
rescence intensities of DCs and macrophages treated with 
PBS were also measured as controls. The actual uptake was 
calculated as the percentage of cells double positive for  
S4-8Qmin (Dil) and CD11c (A660), or S4-8Qmin (Dil) and 
F4/80 (APC-Cy7) markers. 
Mice  
 C57BL/6 (female, 6-8 weeks old) mice were purchased 
from Animal Resources Centre (Perth, Western Australia). 
All animal studies were approved by The University of 
Queensland Animal Ethics Committee (DI/034/11/NHMRC) 
and performed according to Australia National Health and 
Medical Research Council (NHMRC) guidelines. 
Tumor Cells 
 TC-1 cells, a mouse C57BL/6 lung epithelial cell line 
transformed with ras oncogenes, HPV-16 E6 and E7, were 
kindly provided by TC Wu [16]. TC-1 cells were cultured in 
RPMI 1640 medium (Gibco) supplemented with 10% heat 
inactivated fetal bovine serum (Gibco) and 1% nonessential 
amino acids (Sigma-Aldrich) at 37 °C/5% CO2. For injection 
into mice, TC-1 cells were washed with 1× DPBS, trypsinized, 
resuspended and viable cells counted (trypan blue exclu-
sion). 
Immunizations 
 Prior to immunization, groups of C57BL/6 mice (5 per 
group) were injected subcutaneously with 2×105 TC-1 tumor 
cells/mouse suspended in 100 µL 1× DPBS in the right flank 
(day 0), and rested for 3 days to allow for tumor formation. 
On day 3 after tumor implantation, mice subsequently re-
ceived a single subcutaneous immunization (100 µL total 
volume/mouse) at the tail base. This consisted of 100 µg of 
S4-8Qmin (equivalent of 30 µg of 8Qmin epitope) in a total 
volume of 100 µL 1× DPBS (in 6 groups) or 1× DPBS (un-
treated control group). The size of the tumors was measured 
every two days using calipers (and palpation) for each 
mouse. The tumor volume was calculated using the formula 
[17]: 
Tumor volume (cm3) = π × [largest diameter × (perpendicu-
lar diameter)2]/6 
 The mice were euthanized when tumors volume was 
greater than 1 cm3 or tumor bleeding was observed. 
In vivo Antibody Depletion Experiments 
 In vivo antibody depletions have been described previ-
ously [18]. The antibody depletions were started prior to 
immunization. Groups of mice (5 groups vaccinated with  
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S4-8Qmin, 5 mice per group) were injected intraperitoneally 
(i.p.) with either 0.5 mg of anti-CD4+ (clone GK 1.5, BioX-
cell) [19], 0.5 mg of anti-CD8+ (clone 53-6.72, BioXcell) 
[19], 0.5 mg of anti-NK (PK136, BioXcell) [16] or 0.5 mg of 
control antibody (rat-IgG and mouse-IgG, BioXcell). Each 
antibody (100 µL) was administered i.p. on day −1, 0, 1 and 
once per week throughout the experiment. This antibody 
treatment resulted in greater than 99% depletion of CD4+ and 
CD8+ T-cells, and 92% depletion of NK cells as assessed by 
flow cytometry. Depleted mice were subsequently chal-
lenged with TC-1 tumor on day 0 and immunized with vac-
cine S4-8Qmin or PBS on day 3. 
Statistical Analysis 
 GraphPad Prism 6 software was used for data analysis. 
Results of tumor volumes among all treatments were evalu-
ated by ANOVA test. Kaplan-Meier survival curves was 
used for the analysis of tumor challenge experiments. Statis-
tical significance was considered when p< 0.05.  
RESULTS AND DISCUSSION 
 We designed and synthesized polymer-peptide chimeras 
consisting of a polyacrylate core and multiple copies  
of 8Qmin (QAEPDRAHYNIVTF; E744-57). The conjugate, 
S4-8Qmin, was synthesized by copper-catalyzed alkyne–azide 
1,3-dipolar cycloaddition (CuAAC) “click” reaction of 
polymer S4 with the peptide epitope 8Qmin in the presence of 
copper wires (Scheme 1), then self-assembled into particles. 
Elemental analysis was used to confirm formation of the 
product [7] as the conjugate contained higher nitrogen/ car-
bon ratio (N/C = 0.085) in comparison to that of S4  
(N/C = 0.004). The exact substitution of polymer core with 
the peptide epitopes was calculated based on the comparison 
of theoretical and observed N/C ratios. The efficacy of con-
jugation was high (88% substitution). The S4-8Qmin was self-
assembled into microparticles with an average diameter of 
12 µm and narrow size distribution (span < 1.2). The  
S4-8Qmin was built with a hydrophobic polymer core and a 
hydrophilic peptide epitope. It was demonstrated that the 
balance between hydrophilic and hydrophobic properties of 
individual segments of such amphiphiles was responsible for 
the size of formed particles and the less polar peptide epi-
topes attached to the polymer core produced larger particles 
[20]. The production process was highly reproducible in 
terms of both substitution ratio and size. 
 The HPV-16 E7 protein epitope 8Qmin (QAEPDRA-
HYNIVTF; E744-57) contained a CTL epitope (CD8+ CTL) 
and a T-helper cell (CD4+) epitope (Fig. 1) [21]. This com-
bination made 8Qmin a promising candidate to stimulate im-
mune responses against tumor cells. As peptides themselves 
are very poor immunogens, an additional adjuvant and/or 
delivery system is essential to induce strong immune re-
sponses. Dendrimers are synthetic polymers with well-
defined structure which may have similar properties to that 
of biomolecules and antigens [22]. The antigens can be 
conjugated to the periphery of dednrimer “arms” to creat 
multifunctional bio-macromolecule. We have selected poly-
acrylate as the most promising candidate for vaccine delivery 
as polyacrylic acid and its esters are easy to synthesize, have 
very limited toxicity and were reported to possess adjuvant-
ing properties when mixed with an inactivated virus [23, 24]. 
Here, the 8Qmin epitope was applied as an antigen, while S4 
acted as a delivery platform. We have reported previously 
that polyacrylate polymer conjugated to peptide epitopes 
were capable to shrink and eradicate TC-1 tumor expressing 
E7 protein in the mouse model [9]. However, biological 
evaluation has not yet been performed to demonstrate immu-
nological properties of this construct. 
 
 
Scheme (1). Synthesis of polymer-peptide conjugates S4-8Qmin. 
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 Antigen presenting cells (APCs) play a crucial role in 
triggering an immune response. They continuously sample 
and process the antigens and present them to CD8+and CD4+ 
T-cells via MHC-I and MHC-II molecules, respectively [25]. 
Antigens in particle form are expected to be efficiently taken 
up by APCs [26]. It has also been demonstrated that only the 
particles, which were efficiently taken up by DCs, induced a 
strong antigen-speciﬁc CD8+ T-cell response [27]. Thus, in 
the present study, we investigated the in vitro uptake of con-
jugate S4-8Qmin by DCs and macrophages by incubating 
labeled S4-8Qmin with DCs and macrophages derived from 
splenocytes. The resulting cell-associated fluorescence (Dil 
labeled S4-8Qmin and CD11c-A660 or F4/8- APC-Cy7) was 
measured by flow cytometry. Approximately 25% of DCs 
and 15% of macrophages showed uptake of S4-8Qmin (Fig. 2). 
Interestingly, despite their relatively large size the particles 
were more efficiently taken up by DCs than macrophages 
(although the opposite trend was expected [28]); however, 
this difference was not statistically significant. 
 
 
 
Fig. (2). Uptake of S4-8Qmin by mice splenocyte-derived DCs and 
macrophages. The experiments were performed in triplicate, and 
data are presented as a percentage of cells double positive for  
S4-8Qmin (Dil) and CD11c (A660) or F4/80 (APC-Cy7). CD11c 
(A660) or F4/80 (APC-Cy7) were markers characteristic of DCs 
and macrophages, respectively. Bars represent the mean ± S.D. of 
three experiments. 
 
 To determine the ability of the vaccine candidate (with-
out the presence of any adjuvant) to induce a lymphocytic 
response, in vivo antibody depletion experiments were per-
formed [18]. Five groups of mice were injected with anti-
CD4+, anti-CD8+, anti-NK, control rat-IgG and control 
mouse-IgG antibodies. Then, tumor cells were injected, and 
the vaccine candidate was administrated in a single dose 3 
days later. Treatments with PBS and S4-8Qmin without de-
pleting antibodies served as the untreated and treated con-
trols, respectively. All mice immunized with PBS, S4-8Qmin/ 
anti-CD8+ and S4-8Qmin/anti-CD4+ were sacrificed due to 
tumor burden by day 29, 27 and 29, respectively (Fig. 3a).  
In contrast, the survival rate of the mice immunized with  
S4-8Qmin, S4-8Qmin/rat-IgG, S4-8Qmin/mouse-IgG and  
S4-8Qmin/anti-NK was 40%, 40%, 60% and 20%, respec-
tively. Among the mice groups treated with S4-8Qmin, the 
survival rate was statistically significantly lower only in the 
CD8+-depleted group when compared with mice treated with 
S4-8Qmin only (p<0.01) (Fig. 3a). Tumor-bearing mice 
treated with S4-8Qmin, S4-8Qmin/rat-IgG, S4-8Qmin/mouse-
IgG, S4-8Qmin/anti-CD4+ and S4-8Qmin/anti-NK showed 
slower tumor growth than those treated with S4-8Qmin/anti-
CD8+ (p<0.05) and PBS (Fig. 3b). Mice treated with the con-
jugate but depleted of CD8+ T-cells showed fast tumor 
growth in a manner similar to the untreated control group 
(PBS). These data suggested that S4-8Qmin anti-tumor po-
tency was related to tumor-associated antigen-specific CD8+ 
T-cell responses. Administration of the conjugate might also 
result in stimulation of CD4+ T-cells as all mice in the group 
injected with anti-CD4+ antibodies were moribund within 30 
days (however, the difference in survival rate was not sig-
nificant when compared to the positive control). In previous 
studies on peptide-based HPV vaccine candidates, which 
targeted the E7 oncogene, similar T-cell responses were re-
ported but the use of external adjuvant was essential [29, 30].  
 In this work, we have clearly demonstrated that the 
polymer-peptide conjugate could serve as a self-adjuvanting 
delivery system and the conjugate was promptly taken up by 
APCs and stimulated CD8+ T-cells to produce a therapeutic 
effect against tumor cells. The self-adjuvanting properties of 
the conjugates can be related to their ability to form particles. 
[28, 31]. It has been demonstrated that antigens in particle 
form are expected to be more efficiently taken up by APCs 
[26]. In addition, large particles are able to induce strong 
immune responses through the depot effect (i.e., retention 
and slow release of an antigen at the injection site) [32]. 
Along the same line, activation of cellular immunity is often 
enhanced by depot-forming adjuvants, which elongate time 
of antigen presentation to the immune cells [31]. Thus, it 
might be assumed that microparticles, presented here, have 
formed a depot and have the ability to induce cellular immu-
nity following uptake by peripheral APCs. Though, the in-
duction of immunity as a consequence of disaggregation of 
these self-assembled particles and slow release of the conju-
gate in the form of single molecules or smaller particles can-
not be ruled out. 
CONCLUSION 
 In conclusion, we synthesized and evaluated a delivery 
system for anti-cancer peptide-based vaccines. This delivery 
system, based on a polyacrylate polymer conjugated with 
HPV-16 E7 protein-derived peptide epitope, induced potent 
therapeutic immune responses against a tumor without the 
use of additional adjuvant. Until now, the ability of self-
assembled polymer-peptide conjugates to induce CD8+ CTL 
immunity has not been proven. In this work, we have shown 
that the polymer-peptide conjugate S4-8Qmin was efficiently 
taken up by APCs, that is, DCs and macrophages, and CD8+ 
CTLs have played a major role in the anti-tumor immunity 
induced by S4-8Qmin. Thus, we have developed the first self-
adjuvanting therapeutic peptide vaccine delivery system 
against cervical cancer. We believe that this strategy can be 
  
Fig. (1). The sequence of the 8Qmin and incorporated CTL (CD8+) 
and the T-helper cell (CD4+) epitopes. 
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used to design other therapeutics that will be able to trigger 
CTL responses against targeted diseases. 
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5.1 Introduction to this publication 
This chapter was submitted to the Journal of Medicinal Chemistry as an original investigation. 
Following previous studies, several new polymer-based delivery systems were designed to create an 
efficient self-adjuvanting peptide-based vaccine against cancer. In this paper, the synthesis of 
conjugates, in vivo tumor challenge experiments, in vitro APC uptake and in vivo activation of T 
cells were presented. It was shown that this delivery system could serve as an efficient and safe 
self-adjuvanting platform for the induction of antigen-specific immune responses with therapeutic 
anti-cancer activity. 
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ABSTRACT: Vaccination can provide a safe alternative to chemotherapy by using the body’s natural defense mechanisms to
create a potent immune response against tumor cells. Peptide-based therapeutic vaccines against human papillomavirus (HPV)-
related cancers are usually designed to elicit cytotoxic T cell responses by targeting the HPV-16 E7 oncoprotein. However,
peptides alone lack immunogenicity, and an additional adjuvant or external delivery system is required. In this study, we
developed new polymer−peptide conjugates to create an eﬃcient self-adjuvanting system for peptide-based therapeutic vaccines.
These conjugates reduced tumor growth and eradicated E7-positive TC-1 tumors in mice after a “single shot” immunization,
without the help from an external adjuvant. The new conjugates had a signiﬁcantly higher anticancer eﬃcacy than the antigen
formulated with a commercial adjuvant. Furthermore, the polymer−peptide conjugates were promptly taken up by antigen
presenting cells, including dendritic cells and macrophages, and eﬃciently activated CD4+ T-helper cells and CD8+ cytotoxic T
lymphocyte cells.
■ INTRODUCTION
Vaccines are one of the most cost-eﬀective public health
interventions and oﬀer a promising strategy for the treatment of
cancer.1 The development of safe and eﬀective therapeutic
cancer vaccines is an urgent and challenging medical need.
Cervical cancer is the second most common cause of cancer
death in women worldwide and results from infection with
human papillomavirus (HPV), most commonly HPV type 16
(HPV-16).2 The HPV-16 E7 oncoprotein is required for
tumorigenesis and maintenance of tumor growth; thus, it has
been used extensively in the development of therapeutic
vaccines to elicit cytotoxic T cell responses (cellular immunity)
against HPV-related cancers.3
Peptide-based vaccines are highly promising for the develop-
ment of therapeutic HPV vaccines because of their safety,
stability, and ease of production.4 The use of a whole protein
vaccine is unsafe because HPV oncoproteins can induce
genomic instability in normal human cells. Instead, peptide-
based vaccines use a minimal nononcogenic epitope to
stimulate an antigen-speciﬁc immune response. In general,
peptides alone are nonimmunogenic. In order to induce
adequate immune responses for vaccines composed of a
synthetic peptide or subunit antigen, an appropriate adjuvant
(immunostimulant) is required to produce the desired immune
response.4 To date, a limited number of adjuvants have been
approved for human use: alum is the only vaccine adjuvant that
is approved worldwide. However, alum only enhances anti-
body-mediated immune responses and fails to stimulate cell-
mediated immunity.5,6 In contrast, microorganism-derived
experimental adjuvants are often highly immunogenic but
toxic.5 Therefore, the discovery and development of novel
adjuvants or self-adjuvanting delivery systems without adverse
toxicity is a key focus in the ﬁeld of peptide-based vaccines.
Previous work in our laboratory has led to the development
of polymer−peptide conjugates as self-adjuvanting delivery
systems for peptide antigens.7−9 We have demonstrated the
ability of B cell epitopes conjugated to the periphery of
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polyacrylate dendrimers to act as a self-adjuvanting vaccine and
induce protective (humoral) immunity against Group A
Streptococcus (Streptococcus pyogenes or GAS) infection. While
a large number of experimental self-adjuvanting systems and
adjuvants can induce humoral immunity, the induction of
cellular immunity with a therapeutic antitumor eﬀect is
particularly challenging.10 There has been considerable interest
in developing potent and eﬃcient peptide-based delivery
systems to stimulate a cellular immune response without the
use of an external adjuvant.11 Recently, we also reported that a
4-arm star polymer-based delivery system could be used in the
design of peptide-based vaccine to reduce and/or eradicate E7-
positive tumor cells in a mouse model. Among the tested
epitopes, only 8Qmin (E744−57, QAEPDRAHYNIVTF) con-
jugated to a 4-arm star polyacrylate polymer was able to reduce
tumor growth in all tested mice and eradicate E7-positive TC-1
tumors in 40% of tested animals.12
In this study, we aimed to assess the ability of a variety of
polyacrylate polymers to induce antitumor immunity in mice.
All vaccine candidates (Scheme 1) included the peptide epitope
8Qmin derived from the HPV-16 E7 oncoprotein as an antigen
because it contains a CTL epitope (CD8+, cytotoxic T
lymphocytes) and a T-helper cell epitope (CD4+) (Figure
1).13 The 8Qmin antigenic epitope was conjugated to four
diﬀerent delivery systems: a linear poly(t-butyl acrylate)
polymer 1, a branched linear polymer 2, a 4-arm star polymer
3, and a 4-arm dendritic polymer 4 (Scheme 1). In cancer
immunotherapy, activation of CD4+ T-helper cells and, in
particular, CD8+ cytotoxic T lymphocyte cells have been
correlated with ability to reduce tumor growth.14 Professional
antigen presenting cells (APCs), such as dendritic cells (DCs)
and macrophages are also critical components of an antitumor
immune cascade.4 Therefore, we have assessed the uptake of all
polymer−peptide conjugates by DCs and macrophages, in
addition to the activation of CD4+ cells and CD8+ cells by the
most potent vaccine candidate.
■ RESULTS
Synthesis and Characterization of Polymer−Peptide
Conjugates. Alkyne-functionalized poly(t-butyl acrylate)
polymers with a diﬀerent number of alkyne moieties (1−4)
were synthesized by atom-transfer radical polymerization
(ATRP) and end-group functionalization. The epitope
(8Qmin) and its azide form (N3CH2C(O)-QAEPDRAHY-
NIVTF-NH2) were synthesized as previously reported.
12,15
Copper (wire)-catalyzed alkyne−azide cycloaddition
(CuAAC)7,16 was chosen for the conjugation of 8Qmin azide
to each polymer to produce the vaccine candidates 5−8
(Scheme 1). All of the products were self-assembled into
particles via the solvent replacement method (DMF/water)
followed by dialysis against water to remove the organic solvent
and excess unreacted peptide and copper. The trace level of
copper present in the puriﬁed polymer−peptide conjugates was
precisely determined by inductively coupled plasma optical
Scheme 1. Synthesis of Vaccine Candidatesa
a(a) Polymers 1−4 were used in the (b) cycloaddition reaction to form polymer−peptide conjugates 5−8.
Figure 1. Amino acid sequence of the 8Qmin epitope. The CTL
epitope (CD8+) and T-helper cell (CD4+) epitope are highlighted
within the 8Qmin sequence.
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emission spectroscopy. The copper content in all of the
conjugates was below 100 ppb (the recommended health
standard level of copper is ≤15 ppm).17 The formation of each
polymer−peptide conjugate was conﬁrmed by elemental
analysis,7,12 which showed a signiﬁcant increase in the
nitrogen/carbon ratio (N/C = 0.082 for 5, N/C = 0.143 for
6, N/C = 0.078 for 7, and N/C = 0.124 for 8) compared with
that of the polymer (N/C = 0.004 for 1 and 2; N/C = 0.02 for
3 and 4), due to the presence of a nitrogen-rich peptide in the
conjugates. The substitution ratio of 8Qmin conjugated to each
polymer was calculated by comparison of the observed and
theoretical N/C ratio for the conjugates as previously
reported.7,12 Compounds 5 (96% substitution) and 6 (98%
substitution) were obtained and considered to be fully
substituted conjugates, while the substitution ratio of 7 and 8
was 88% and 76%, respectively. The conjugation of 8Qmin to
each polymer followed by self-assembly and dialysis was
repeated multiple times, producing virtually identical products
with the same substitution ratio and particle size. This was
conﬁrmed by elemental analysis and laser diﬀraction,
respectively.
Samples were prepared for in vivo experiments by
formulating all polymer−peptide conjugates in phosphate
buﬀer saline (PBS). All conjugates formed a milky suspension
upon addition of the buﬀer (pH 7.4). The polymer−peptide
conjugates 5, 6, 7, and 8 formed large particles of 17 μm, 12
μm, 12 μm, and 13 μm in diameter, respectively (Supporting
Information, Figure S1). The size distribution of all conjugates
was narrow (5, span = 2.0; 6, span = 1.7; 7, span = 1.1; and 8,
span =1.7).
In Vivo Tumor Treatments. The eﬀect of diﬀerent
polymeric structures on the therapeutic potency of polymer−
peptide conjugates was examined by conjugating the 8Qmin
epitope with linear polymers 1 and 2, star polymer 3, and
dendritic polymer 4 (Scheme 1). Mice (10 per group) were
immunized with compounds 5−8 or control groups on the
third day after implantation with tumor cells.18,19 The positive
control group (8Qmin + ISA51) received 8Qmin emulsiﬁed in
Montanide ISA51 (IFA-like adjuvant), while PBS was
administered to the negative control group. The Kaplan−
Meier survival curve (Figure 2a) showed that 100% of mice
treated with PBS were euthanized due to tumor burden by day
43. In contrast, the survival rate in the mice treated with any of
the four conjugates were similar to, or better, than that of the
positive control (8Qmin + ISA51). Compound 7 showed
eﬃcacy similar to that of the positive control group (consistent
with previous observations),12 while 5, 6, and 8 showed 90%
survival rate and signiﬁcantly improved survival compared with
the positive control. As shown in Figure 2b, tumor-bearing
mice treated with any of the four conjugates and positive
control showed slower tumor growth than the PBS-only group.
Only one mouse treated with 8 developed a tumor, while three
mice developed tumors when treated with 5 and only two mice
with 6 (Supporting Information Figure S2). Thus, the dendritic
construct 8 showed the best therapeutic properties. However,
when compared directly, there is no statistically signiﬁcant
diﬀerence in mouse survival rate that were treated with linear
(5 and 6) and dendritic (8) vaccine constructs.
Uptake of Polymer−Peptide Conjugates by Dendritic
Cells and Macrophages. The uptake of all polymer−peptide
conjugates by DCs and macrophages was investigated by
incubating murine splenocytes with ﬂuorescently dye (Dil)-
labeled conjugates. The resulting cell-associated ﬂuorescence
(CD11c labeled with A660, F4/8 labeled with APC-Cy7) was
measured by ﬂow cytometry. The DC and macrophage uptake
of all four conjugates was signiﬁcantly higher than that of the
negative control (PBS, Figure 3, Supporting Information Figure
S3). Of the four conjugates, 7 showed lower uptake by both
DCs and macrophages than other polymer−peptide conjugates,
while 8 showed the highest uptake by APCs. The uptake of 8
Figure 2. In vivo tumor treatment experiments. C57BL/6 (10 per
group) were inoculated subcutaneously in the right ﬂank with 2 × 105
TC-1 cells/mouse (day 0) and vaccinated with diﬀerent immunogens
on day 3 without an additional boost. (a) Survival rate monitored over
60 days post-implantation and time to death plotted on a Kaplan−
Meier survival curve. Mice were euthanized when tumor volume
reached 1 cm3 or they started bleeding. The survival rate of each group
was compared to the positive control (8Qmin + ISA51) (ns p > 0.05; *
p < 0.05). (b) Mean tumor volume (cm3) in diﬀerent groups of mice
post-implantation. Tumor volume is plotted until the ﬁrst mouse from
any group was euthanized (day 29).
Figure 3. Uptake of 5−8 by mouse splenocyte-derived DCs and
macrophages. Dextran was used as a positive control. The experiments
were performed in triplicate, and data are presented as percentage of
cells double positive for conjugates (labeled with Dil) and CD11c
(A660) or F4/80 (APC-Cy7). CD11c (A660) or F4/80 (APC-Cy7)
were markers characteristic of DCs and macrophages, respectively.
Bars represent the mean ± standard deviation of three experiments.
The uptake of each conjugate group was compared to the PBS control
group (ns p > 0.05; * p < 0.05; ** p < 0.01; *** p < 0.001).
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by DCs was also conﬁrmed by confocal microscopy
(Supporting Information Figure S4). Overall, the uptake of
the conjugates was biased toward DCs rather than macro-
phages, and the diﬀerence in uptake of the four polymeric
delivery systems was not statistically signiﬁcant.
In Vivo CD4+ and CD8+ T Cell Activation. Early
activation of the immune system was measured by monitoring
CD11a and CD49d expression by T cells20,21 7 days after mice
were immunized with the lead vaccine candidate 8. Both 8 and
8Qmin + ISA51 achieved signiﬁcantly higher activation of
peripheral CD4+ T cells and CD8+ T cells when compared with
that of PBS (Figure 4).
Hemolytic Assay. A hemolytic assay was performed to test
whether the amphiphilic constructs disrupted biological
membranes due to their surfactant-like properties. Even at
high concentrations (1 mg/mL), the compounds did not
disrupt erythrocyte membranes (Supporting Information,
Figure S5).
■ DISCUSSION
Peptide-based vaccines are considered to be a promising
candidate for the development of therapeutic vaccines to treat
cancer. Poor immunogenicity is a signiﬁcant challenge in the
development of peptide-based vaccines; thus, an appropriate
adjuvant (immunostimulant) or delivery system is required to
elicit the desired immune response. Existing approved
adjuvants are ineﬀective at stimulating the cellular immune
response needed for an eﬀective anticancer vaccine.22
Furthermore, most experimental adjuvants are unsuitable for
human use because of serious adverse side eﬀects.4 Safe and
robust adjuvants or self-adjuvanting delivery systems are in high
demand to overcome obstacles in the ﬁeld of peptide-based
vaccines.
Polymer carriers have been studied for vaccine delivery for
many years, and a self-assembling amphiphilic polymer has
been suggested as a likely platform for the development of
peptide-based subunit vaccines.23 We selected polyacrylate as
the most promising antigen carrier because poly(acrylic acid)
and its esters were easy to synthesize and are known to possess
some adjuvanting activity when physically mixed with
inactivated viral antigens.24 In addition, their safety proﬁle is
well established, and analogues of polyacrylate have been used
for pharmaceutical applications since the 1960s.25 We recently
identiﬁed a peptide epitope 8Qmin which, upon conjugation to a
4-arm star polyacrylate polymer, reduced tumor growth in mice
after a single immunization without the addition of an external
adjuvant.12 It was also demonstrated that the depletion of
CD8+ cells diminished S4−8Qmin (7) antitumor activity,
suggesting that S4−8Qmin (7) acted through CD8+ T cells, a
desirable characteristic for an anticancer vaccine.26
To improve the ability of this polymer−peptide-based
delivery system to induce antitumor activity, we designed
four diﬀerent polyacrylate polymer analogues as the delivery
platform for peptide antigen 8Qmin, each with a diﬀerent
number of alkyne functional groups12 (Scheme 1). These four
polyacrylate polymer analogues were a linear polymer with one
alkyne functional group (1), a branched linear polymer with
two alkyne functional groups (2), a 4-arm star polymer with
four alkyne functional groups (3), and a dendritic polymer with
eight alkyne functional groups (4). Triprop-2-ynylamine was
conjugated to both 4-arm star and linear polymers, resulting in
eight or two alkyne functional groups, respectively. The
polymer’s periphery of alkyne functional groups enabled
conjugation to the azide-functionalized 8Qmin epitope. The
polymer−peptide vaccine candidates 5−8 were synthesized via
CuAAC “click” reaction using copper wire as a catalyst
(Scheme 1). The copper wire was easily removed upon
completion of the “click” reaction, and residual soluble copper
was dialyzed from the solution, leaving only trace copper
(below 100 ppb) in the puriﬁed conjugates. Copper wire can be
easily reused for future reactions27 and allowed the “click”
reaction to proceed without the use of Cu (I) stabilizing and/or
Cu (II) reducing agents, minimizing undesirable contaminants
in the ﬁnal product. The hydrophobic polymeric (PtBA) core
and single or multiple copies of the hydrophilic 8Qmin epitope
resulted in amphiphilic vaccine candidates that self-assembled
into 12−17 μm particles when formulated in PBS. All
conjugates were also assessed toward their toxicity to
erythrocytes because amphiphilic compounds possessing a
signiﬁcant degree of hydrophobicity may have some biological
membrane damaging properties. There was no apparent sign of
toxicity to erythrocytes for all of the conjugates as conﬁrmed by
the hemolysis assay (Supporting Information, Figure S4).
The inﬂuence of diﬀerent polymeric structures on the
therapeutic potency of polymer−peptide conjugates was tested
by immunizing mice with the test conjugates or control groups
Figure 4. Immune responses induced by polymer−peptide conjugate
8. Groups of C57BL/6 mice (5 per group) were given a single
subcutaneous immunization with 8 or control formulations. Positive
control received 8Qmin emulsiﬁed in Montanide ISA51 (8Qmin +
ISA51). The negative control was administered PBS. Phenotypes of
circulating CD4+ and CD8+ cells were assessed on day 7 after
vaccination. Each spot represents one mouse. Horizontal bars
represent means. In vivo (a) CD4+ and (b) CD8+ activation of each
conjugate group was compared to those of the PBS control group (ns
p > 0.05; * p < 0.05).
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on day 3 after tumor implantation. All conjugates stimulated
therapeutic immunity in tumor-bearing mice. Vaccination
signiﬁcantly improved mouse survival and reduced tumor
growth when compared with thos in the untreated PBS group
(Figure 2). Among the tested formulations, the linear polymer-
based conjugates 5 and 6, and dendritic polymer-based
conjugate 8 elicited signiﬁcantly better survival rates than
8Qmin + ISA51, while 7 showed antitumor eﬃcacy similar to
that of the adjuvant-based control formulation. In particular, 8
induced an excellent therapeutic response with only one mouse
developing a tumor (Supporting Information, Figure S2). The
role of particle size in inducing an immune response is debated
in the literature. Some reports mentioned that immune
responses were signiﬁcantly stronger for small nanoparticles
(less than 100 nm),23,28 while others claimed that micro-
particles were necessary for strong activation of the immune
system.29,30 Neverlethess, all four conjugates formed particles of
a similar size (12−17 μm), suggesting that the diﬀerences in
their antitumor activity were not size dependent. The
substitution ratio of the peptide epitope conjugated to the
polymer also did not correlate with the antitumor eﬃcacy of
the constructs.
APCs, including DCs and macrophages, play a crucial role in
triggering an immune response, which is initiated by antigen
uptake. APCs continuously sample and process antigens in
their surroundings and present them via MHC-I and MHC-II
molecules to CD8+ and CD4+ T cells, respectively.4 Eﬃcient
particle uptake by DCs was necessary to induce strong antigen-
speciﬁc CD8+ T cell responses.23 The depot eﬀect (retention of
the antigen at the injection site) is believed to stimulate
immune responses against large particles, and similarly, depot-
inducing adjuvants are responsible for T cell activations
through uptake by peripheral APCs.29,31 Thus, the ability of
APCs to take up the conjugates was assessed. All four
conjugates were shown to induce signiﬁcant uptake by DCs
and macrophages when compared to that of PBS (Figure 3 and
Figure S3, Supporting Information). Compound 7 showed
lower uptake by both DCs and macrophages than the other
polymer−peptide conjugates, while 8 showed higher uptake by
both DCs and macrophages. Thus, APC uptake of the particles
correlated well with the antitumor eﬀect stimulated by the
vaccine candidates.
In general, research into therapeutic cancer vaccines has
aimed to induce antigen-speciﬁc activation of both CD4+ T-
helper cells and CD8+ cytotoxic T lymphocyte cells. Inclusion
of CD4+ T-helper and CD8+ T cell epitopes in the vaccine
formulation is important and allows the peptide antigen to elicit
potent speciﬁc T cell immune responses against tumors.3,4 The
8Qmin peptide used in this study included a CD8
+ T cell
epitope (E749−57) and a CD4
+ T-helper cell epitope (E748−54)
from the E7 protein (Figure 1).13 The antigen-speciﬁc immune
responses elicited by the most potent vaccine candidate 8 was
evaluated for its ability to activate CD8+ and CD4+ T cells.
Compound 8 eﬃciently activated CD4+ T-helper cells and
CD8+ cytotoxic T lymphocyte cells, and showed potency
similar to that of the peptide emulsiﬁed in the reference
adjuvant (Figure 4). Furthermore, the production of epitope-
speciﬁc antibodies was not detected (data not shown),
consistent with our goal of stimulating cellular immunity to
target tumor antigens.
■ CONCLUSIONS
The polymer−peptide conjugates produced a robust therapeu-
tic eﬀect against a tumor after a single immunization without
the help of an external adjuvant. We also demonstrated that the
lead vaccine conjugate 8 induced more potent antitumor
activity than a formulation that incorporated a classical
adjuvant, was eﬃciently taken up by DCs and macrophages,
and stimulated signiﬁcant CD8+ and CD4+ T cell activation.
Interestingly, less sophisticated analogues of the lead
compound that possessed a linear polymer moiety (5 and 6)
induced similar immune responses to 8 and may be used as a
simpler and cheaper alternative for further vaccine develop-
ment. Compound 8 was chosen as the lead vaccine candidate
due to its slightly better eﬃcacy and potential for future
conjugation of multiple epitopes to enhance the antigen-speciﬁc
immune response against the HPV tumor. Our ﬁndings suggest
that this polymer−peptide conjugate delivery system is a
promising strategy for the design of other therapeutic peptide-
based vaccines that induce adequate cellular immunity against a
target disease. This delivery system also removes the use of
incompletely deﬁned and ordinarily toxic immune adjuvants,
producing a safe and eﬀective therapeutic vaccine for human
use.
■ EXPERIMENTAL SECTION
Materials. N,N′-Dimethylformamide (DMF) and methanol were
obtained from Merck (Hohenbrunn, Germany). Cu wires were
purchased from Aldrich (Steinheim, Germany). t-Butyl acrylate (tBA,
Aldrich, >99%) was deinhibited before use by passing through a basic
alumina column, ethyl 2-bromoisobutyrate (EBiB, Aldrich, 98%),
tripropargylamine (TPA, Aldrich, 98%), sodium azide (NaN3, Aldrich,
≥ 99.5%), dimethyl sulfoxide (DMSO, Labscan, AR grade),
N,N,N′,N′,N″-pentamethyldiethylenetri-amine (PMDETA, Aldrich,
99%), copper(I) bromide (Cu(I)Br, MV Laboratories, INC.,
99.999%), and copper(II) bromide (CuBr2, Aldrich, 99%) were used
as received. Propargyl nitroxide was synthesized according a previously
reported procedure.32 All other reagents were obtained at the highest
available purity from Sigma-Aldrich (Castle Hill, NSW, Australia). The
peptide epitope (8Qmin) and its azide form (N3CH2C(O)-QAEP-
DRAHYNIVTF-NH2) were synthesized and conﬁrmed to be >95%
pure by HPLC methods as previously reported.12
Equipment. 1H nuclear magnetic resonance (1H NMR) spectra
were recorded with a Bruker Avance 300 MHz spectrometer (Bruker
Biospin, Germany). The particle size distribution and measurement of
the average particle size were analyzed using a laser particle size
analyzer Mastersizer 2000 (Malvern Instruments, England, UK).
Multiplicate measurements were performed, and the average particle
size was represented using the value of the volume moment. The
images of particle uptake by dendritic cells were obtained using a
ZEISS LSM 510 META confocal microscope. The software used for
image acquisition was AIM 4.2 (Carl Zeiss, Ltd.) and Carl Zeiss Zen
2009 for image analysis. The trace level of copper present in the
polymer−peptide conjugates was precisely determined by inductively
coupled plasma optical emission spectrometery (PerkinElmer Optima
8300DV (Dual View), USA).
Synthesis of Linear P(tBA37)-Br by ATRP. [
tBA]/[EBiB]/
[CuBr]/[CuBr2/PMDETA]/[PMDETA] = [80]:[1]:[0.75]:[0.15]:
[0.75]. Freshly puriﬁed t-BA (12.8 g, 0.10 mol), PMDETA (0.162 g,
9.38 × 10−4 mol), preformed CuBr2/PMDETA (0.074 g, 1.88 × 10
−4
mol), EBiB (0.244 g, 1.25 × 10−3 mol), and 4 mL of acetone were
added to a 25 mL Schlenk ﬂask equipped with a magnetic stirrer and
purged with Ar for 20 min. CuBr (0.134 g, 9.38 × 10−4 mol) was
added under positive N2 ﬂow and purged with N2 for a further 10 min.
The ﬂask was placed in a temperature controlled oil bath at 50 °C for
2 h. The reaction was terminated by quenching in liquid nitrogen
followed by exposure to air. The polymerization mixture was diluted
with THF, and the copper salts were removed by passage through an
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activated basic alumina column. The solution was concentrated
through evaporation with air ﬂow, and the polymer recovered by
precipitation into methanol/water (50:50 vol), ﬁltered, and dried for
48 h under high vacuum at 25 °C. The polymer was characterized by
GPC. (Mn = 5000, PDI = 1.09, P(t-BA37)-Br).
Synthesis of Linear P(tBA37)-N3. NaN3 (0.225 g, 3.46 × 10
−3
mol) was added to a stirred solution of PtBA37-Br (1.50 g, 3.0 × 10
−4
mol) in 5 mL of DMF. The reaction mixture was stirred for 24 h at
R.T. The polymer was recovered by precipitation into methanol/water
(50:50 vol), ﬁltered, and then dried under high vacuum at 25 °C.
Synthesis of Polyacrylate-Based Linear Polymer 1. PtBA37-Br
(0.50 g, 1.0 × 10−4 mol), propargyl nitroxide (25.2 mg, 1.2 × 10−4
mol), and Me6TREN (27.6 mg, 1.2 × 10
−4 mol) were dissolved in a
DMSO/toluene mixture (1.5 mL/2 mL) in a 10 mL Schlenk tube. The
mixture was purged by Ar for 20 min, and then CuBr (17.2 mg, 1.2 ×
10−4 mol) was added. The reaction was stirred for 1 h at R.T., and the
mixture was diluted with chloroform (10 mL). The solution was
washed with deionized water to remove most of the DMSO and
Cu(II) complex. The chloroform phase was dried over MgSO4 and
passed through a small Al2O3 column to remove the copper complex.
The solution was blown dry and puriﬁed by preparative GPC. GPC:
Mn = 5270; PDI = 1.05. 1H NMR (CDCl3): δ 1.11−1.23 (m, 21H,
methyl groups of both initiator residual and TEMPO ring), 1.43 (b,
methyl protons of t-BA repeat units), 1.82, 2.21 (b, methylene and
methine protons of polymer backbone), 2.40 (s, 1H, (−OCH2−C
CH)), 3.76 (b, 1H, methine proton on TEMPO ring), 3.97 (m, 2H,
methylene protons of initiator residual), 4.07 (m, 1H, methine proton
of t-BA unit close to the alkoxyamine linkage).
Synthesis of Polyacrylate-Based Linear Polymer 2. PtBA37-N3
(0.44 g, 8.8 × 10−5 mol), TPA (0.23 g, 1.76 × 10−3 mol), and
PMDETA (7.6 mg, 4.4 × 10−5 mol) were dissolved in 2 mL of toluene
in a 10 mL Schlenk tube. The mixture was purged with Ar for 20 min,
and then CuBr (6.3 mg, 4.4 × 10−5 mol) was added under Ar
atmosphere. The reaction was stirred for 1 h at R.T. then diluted with
chloroform (10 mL). The solution was passed through a small Al2O3
column to remove the copper complex, blown dry, and puriﬁed by
preparative GPC. GPC: Mn = 5060; PDI = 1.09.
1H NMR (CDCl3): δ
1.11−1.23 (m, 9H, methyl groups of initiator), 1.43 (b, methyl protons
of t-BA repeat units), 1.82, 2.21 (b, methylene and methine protons of
polymer backbone), 2.40 (s, 1H, (-NCH2−CCH)2), 3.44 (s, 4H,
(-NCH2-CCH)2), 3.85 (s, 2H, methylene protons close to triazole
ring), 4.07 (m, 2H, methylene protons of initiator residual), 5.25 (m,
1H, methine proton of t-BA unit close to triazole ring), 7.63 (m, 1H,
proton of triazole ring).
Synthesis of Polyacrylate-Based Star Polymer 3. Star polymer
3 was synthesized according to a published procedure.12 1H NMR
(CDCl3): δ 1.11−1.21 (m, 15H, methyl group of core and TEMPO
ring), 1.45 (b, methyl protons of t-BA repeat units), 1.81, 2.21 (b,
methylene and methine protons of polymer backbone), 2.40 (s, 4H,
(−OCH2−CCH)4), 3.76 (b, 4H, methine proton on TEMPO ring),
3.80−4.25 (b, 20H, (methylene protons of the core, methine proton of
the t-BA unit close to the alkoxyamine linkage, methylene protons of
propargyl group).
Synthesis of Polyacrylate-Based Dendritic Polymer 4.
Alkyne-functionalized 8-arm poly(t-butyl acrylate) dendrimer 4 was
synthesized by atom-transfer radical polymerization and copper-
catalyzed alkyne−azide 1,3-dipolar cycloaddition (CuAAC) “click”
reaction according to a published procedure.7 1H NMR (CDCl3): δ
1.11 (m, 12H, (CH(CH3))4), 1.45 (b, methyl protons of t-BA
repeat units), 1.82, 2.23 (b, methylene and methine protons of
polymer backbone), 2.47 (m, 4H, (CH(CH3))4), 3.48 (s, 16H,
(-N(-CH2-CCH)2)4), 3.88 (s, 8H, (methylene protons close to the
1,2,3-triazole ring), 3.94−4.22 (m, 8H, C(CH2-O−)4), 5.24 (m, 1H,
methine protons of PtBA close to the 1,2,3-triazole ring) 7.72 (m, 4H,
methine protons of 1,2,3-triazole ring).
Synthesis of Vaccine Candidate 5. 8Qmin azide peptide epitope
(3.0 mg, 1.6 μmol, 4 equiv) and polymer 1 (2.1 mg, 0.14 μmol, 1.0
equiv) were dissolved in DMF (1 mL). Copper wires (60 mg), treated
with concentrated sulfuric acid (3 min), subsequently washed with
distilled water, methanol, and dried under reduced pressure, were
added to the mixture. Nitrogen was brieﬂy bubbled through the
mixture (15 s) to remove most of the oxygen from the reaction. The
reaction mixture was protected from light with aluminum foil and
stirred at 50 °C in a temperature controlled oil bath under nitrogen
atmosphere for 4 h. The copper wires were ﬁltered oﬀ from the warm
solution and washed with 1 mL of DMF. Millipore endotoxin-free
water (5 mL) was slowly added to the solution (at 0.005 mL/min).
Particles formed through the self-assembly process were exhaustively
dialyzed against endotoxin-free water (pH 6.8) using presoaked and
rinsed dialysis bags (Pierce Snakeskin, MWCO 3K). The formation of
the conjugate was conﬁrmed by elemental analysis, which showed a
signiﬁcant increase in the nitrogen/carbon ratio (N/C = 0.082)
compared with that of 1 (N/C = 0.004), due to the presence of a
nitrogen-rich peptide in 5. The substitution ratio was calculated by
comparing the observed and theoretical N/C ratio for the conjugate
and found to be 96%.
Synthesis of Vaccine Candidate 6. Compound 6 was
synthesized in the same manner as that described above. 8Qmin
azide peptide epitope (3.0 mg, 1.6 μmol, 4 equiv) and polymer 2
(2.0 mg, 0.14 μmol, 1.0 equiv) were dissolved in DMF (1 mL). The
reaction was stirred for 4 h under nitrogen atmosphere at 50 °C. The
formation of the conjugate was conﬁrmed by elemental analysis, which
showed a signiﬁcant increase in the nitrogen/carbon ratio (N/C =
0.143) compared with that of 2 (N/C = 0.02), due to the presence of a
nitrogen-rich peptide in 6. The substitution ratio was calculated based
on comparison of the observed and theoretical N/C ratio for the
conjugate and found to be 98%.
Synthesis of Vaccine Candidate 7. Compound 7 was
synthesized in the same manner as that described above. 8Qmin
azide peptide epitope (1.8 mg, 1 μmol, 10 equiv) and polymer 3
(1.9 mg, 0.10 μmol, 1.0 equiv) were dissolved in DMF (1 mL). The
reaction was stirred for 8 h under nitrogen atmosphere at 50 °C. The
formation of the conjugate was conﬁrmed by elemental analysis, which
showed a signiﬁcant increase in the nitrogen/carbon ratio (N/C =
0.078) compared with that of 3 (N/C = 0.004), due to the presence of
a nitrogen-rich peptide in 7. The substitution ratio was calculated
based on comparison of the observed and theoretical N/C ratio for the
conjugate and found to be 88%.
Synthesis of Vaccine Candidate 8. Compound 8 was
synthesized in the same manner as that described above. 8Qmin
azide peptide epitope (3.0 mg, 1.6 μmol, 16 equiv) and polymer 4
(1.9 mg, 0.10 μmol, 1.0 equiv) were dissolved in DMF (1 mL). The
reaction was stirred for 12 h under nitrogen atmosphere at 50 °C. The
formation of the conjugate was conﬁrmed by elemental analysis, which
showed a signiﬁcant increase in the nitrogen/carbon ratio (N/C =
0.124) compared with that of 4 (N/C = 0.02), due to the presence of
the nitrogen-rich peptide in 8. The substitution ratio was calculated
based on comparison of the observed and theoretical N/C ratio for the
conjugate and found to be 76%.
Particle Size Measurement. The particle size and size
distribution (span) of the conjugates was measured by laser diﬀraction
(Mastersizer 2000, Malvern Instruments, UK) after formulation in
PBS. The diameter was presented as the volume median diameter
(D50%). The size distribution (span) value was deﬁned by a standard
formula:
= −span (D90% D10%)/D50%
where D90%, D10%, and D50% are the particle diameters determined
from the 90th, 10th, and 50th percentiles of the undersized particle
distribution curve.33
Mice and Cell Lines. Female C57BL/6 (6−8 weeks old) mice
were used in this study and purchased from the Animal Resources
Centre (Perth, Western Australia). TC-1 cells (murine C57BL/6 lung
epithelial cells transformed with HPV-16 E6/E7 and ras oncogenes)
were provided by TC Wu.34 TC-1 cells were cultured and maintained
at 37 °C/5% CO2 in RPMI 1640 medium (Gibco) supplemented with
10% heat inactivated fetal bovine serum (Gibco) and 1% nonessential
amino acid (Sigma-Aldrich). For injection into mice, TC-1 cells were
washed with 1× PBS, trypsinized, resuspended, and viable cells
counted (trypan blue exclusion). The animal experiments were
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approved by the University of Queensland Animal Ethics committee
(DI/034/11/NHMRC) in accordance with the Australian National
Health and Medical Research Council (NHMRC) animal handling
guidelines.
In Vivo Tumor Treatment Experiments. To test the eﬃcacy of
each polymer−peptide conjugate as a therapeutic vaccine against
established tumors, groups of C57BL/6 mice (10 per group) were ﬁrst
challenged subcutaneously with 2 × 105 TC-1 tumor cells/mouse
suspended in 100 μL of 1× PBS in the right ﬂank (day 0) and rested
for 3 days to allow for tumor formation. On day 3 after tumor
inoculation, the mice received a single subcutaneous immunization at
the tail base of 100 μg (50 μg per side) of polymer−peptide conjugates
in a total volume of 100 μL 1× PBS or control formulations. The
polymer−peptide conjugates 5−8 were tested, while the positive
control group received 30 μg of 8Qmin emulsiﬁed in a total volume of
100 μL of Montanide ISA51 (Seppic, France)/PBS (1:1, v/v), and the
negative control group received 100 μL of 1× PBS. The size of the
tumor was measured every 2 days using calipers (and palpation) for 60
days.35,36 The tumor volume was calculated using the following
formula:36
π= × ×
tumor volume (cm )
[largest diameter (perpendicular diameter) ]/6
3
2
To minimize suﬀering, mice were euthanized when the tumor reached
1 cm3 or started bleeding.
Uptake of Conjugates by Dendritic Cells and Macrophages.
An antigen-presenting cell uptake assay was performed using a method
similar to one previously described.37,38 The uptake of 5−8 by
dendritic cells and macrophages was investigated using splenocytes
marked with CD11c-A660 (eBioscience) or F4/80-APC-Cy7 (BioL-
egend, Paciﬁc Heights Blvd, San Diego, CA, USA) antibodies,
respectively. Single-cell suspensions of mouse spleens were prepared
by passing the organ through a stainless steel mesh. Erythrocytes were
lysed with erythrocyte lysis buﬀer (Sigma-Aldrich), and the remaining
cell population was placed in a 6-well plate at a density of 2 × 105
cells/well in phenol free IMDM Glutamax medium (Gibco, Life
technologies), supplemented with 10% FBS, 50 μM 2-mercaptoetha-
nol (Gibco, Life technologies), 100 U/mL penicillin, and 100 μg/mL
streptomycin (Gibco, Life technologies). All conjugates were labeled
with Dil (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine per-
chlorate) (Vybrant, Life technologies); 0.5 μL of Dil was added to 100
μL of conjugate solution in PBS and incubated for 30 min (Dil was
rapidly adsorbed to the conjugates). Dil-labeled conjugates or Dextran-
FITC (positive control) (Chondrex, Inc., USA) were added to the
wells and incubated overnight. The adherent cells were scraped from
the plate and incubated with Fc-block for 30 min at 4 °C, centrifuged,
and resuspended in buﬀer that contained CD11c-A660 and F4/80-
APC-Cy7 antibodies for 30 min at 4 °C. The cells were then
centrifuged and resuspended in 0.5 mL of FACS buﬀer (PBS, 0.02%
sodium azide, 0.5% BSA) and analyzed using LSR II ﬂow cytometry
(BD Biosciences). The ﬂuorescent intensities of dendritic cells and
macrophages treated with PBS were also measured as a control. The
actual uptake was calculated as the percentage of cells double positive
for conjugate (Dil) and CD11c (A660) or conjugate (Dil) and F4/80
(APC-Cy7) markers.
In Vivo CD4+ and CD8+ T Cell Activation Assay. The activation
of CD4+ and CD8+ T cells by the polymer−peptide conjugate was
assessed using an adaptation of a previously published method.20,21
Groups of C57BL/6 mice (5 per group) were given a single
subcutaneous injection with 100 μg of 8 in a total volume of 100 μL of
1× PBS or control formulations. The positive control received 30 μg
of 8Qmin emulsiﬁed in a total volume of 100 μL of Montanide ISA51
(Seppic, France)/PBS (1:1, v/v). The negative control group was
administered 100 μL of 1× PBS. Seven days after immunization,
mouse blood was collected via a submandibular bleed and collected in
5 mM EDTA in PBS. Samples were centrifuged at 400g for 5 min, and
the supernatant was discarded. Erythrocytes were lysed by
resuspending in 1 mL of ACK lysis buﬀer (150 mM NH4Cl, 1 mM
KHCO3, and 0.1 mM MgNa2EDTA) for 5 min at room temperature.
A second round of RBC lysis was completed as described above. The
resulting cell pellet was resuspended in 100 μL of MACS buﬀer (PBS
[pH 7.2] without Ca2+ and Mg2+, 0.5% w/v bovine serum albumin
(BSA), 2 mM EDTA) and transferred into a 96-well v-bottom plate.
The plate was spun at 400g for 5 min and the supernatant discarded.
Cells were resuspended in 50 μL of Fc block (clone 2.4G2), incubated
on ice for 10 min, and centrifuged as described above. The cell pellet
was resuspended in 50 μL of MACS buﬀer that contained anti-CD4
V500 (Clone RM 4−5), anti-CD8 PerCP-Cy5.5 (Clone 53−6.7), anti-
CD11a FITC (Clone 2D7), and anti-CD49d PE (Clone 9C10)
antibodies (all antibodies from BD Biosciences) and incubated on ice
(protected from light) for 25 min. Compensation controls were
prepared in the same way as the cell sample but using antirat IgG
compensation beads (BD Biosciences) instead of cells (except cells for
CD4 V500). Cells were washed three times with 200 μL of MACS and
centrifuged as described above. Paraformaldehyde (1% aqueous
buﬀered solution, 50 μL) was added, and cells were incubated for 5
min on ice. A ﬁnal wash was done by adding 150 μL of MACS and
centrifuged as described above. The pellet was resuspended in 200 μL
of MACS and transferred into 5 mL of polystyrene tubes (Falcon) that
contained 200 μL of MACS. Samples were run on a BD LSR Fortessa,
and the data were analyzed using FlowJo software, version 10.0.7
(Tree Star). The total leukocyte population was gated on CD4+ and
CD8+ T cells. Antigen-experienced CD4+ T cells were gated as the
percentage of CD4+ T cells double positive for CD49d and CD11a.
Antigen-experienced CD8+ cells were gated as the percentage of CD8+
T cells that are both CD8low and CD11a. Data were graphed using
Prism (Graph Pad).
Hemolytic Assay. The capacity of polymer−peptide conjugates
5−8 to induce hemolysis was examined using a standard hemolytic
assay. Blood was collected from a healthy human volunteer who had
given written informed consent (protocol approved by the University
of Queensland Ethics Committee, approval number 2009000661).
The polymer−peptide conjugates solutions (1 mg/mL in 1× PBS)
were added in 100 μL triplicates to human erythrocytes and incubated
at 37 °C for 1 h. Sodium dodecyl sulfate (SDS) (100 μg/mL) was
used as a positive control and PBS as the negative control. After 1 h,
the plate was centrifuged at 750g for 15 min, and 75 μL of supernatant
per well was transferred to a new 96-well plate. The absorbance of
each sample was recorded at 540 nm using a Spectramax 250
microplate reader. The data were calculated according to a standard
formula:
= − −
×
A A A A% hemolysis [( min )/(max min )]
100%
540 540 540 540
where A540 is the average absorption of sample at 540 nm; minA540 is
the average absorption of PBS (negative control); and maxA540 is the
average absorption of SDS (positive control).
■ STATISTICAL ANALYSIS
All data were analyzed using GraphPad Prism 6 software.
Kaplan−Meier survival curves were applied to the results of the
tumor treatment experiments. Statistical analysis between
groups was determined using the log-rank (Mantel-Cox) test
for survival experiments, two-way ANOVA for the uptake assay,
and the Tukey’s multiple comparisons test for the CD4/CD8
assay. Diﬀerences were considered statistically signiﬁcant when
p < 0.05.
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Figure S1. Hydrodynamic diameter (volume-based particle size) as measured by Mastersizer 
2000 for (a) 5, (b) 6, (c) 7 and (d) 8 in PBS. 
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Figure S2. Development of TC-1 tumor (60 days) in 10 mice treated with (a) 5, (b) 6, (c) 7, 
(d) 8, (e) 8Qmin + ISA51, or (f) PBS. Female C57BL/6 (6-8 week old) mice were challenged 
with TC-1 tumor on day zero. The mice received vaccination on day 3. In panel (a)-(e), mice 
which were euthanized or shown visible tumor at the end of the experiment were marked in 
color.  
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Figure S3. Uptake of compounds 5-8 and controls (PBS and dextran) by (a) DCs and (b) 
macrophages. 
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Figure S4. Confocal microscope images of (a) dendritic cells, (b) 8, and (c) 8 conjugates that 
were taken up by dendritic cells (scale bar: 20 µm). 
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Figure S5. Hemolysis of polymer-peptide conjugates at injectable concentration (1 mg/mL). 
The percentage of hemolysis is calculated by assuming that the positive control SDS will give 
100% hemolysis. Mean and standard deviation of triplicates samples are shown. 
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5.3 Vaccine safety issue 
The safety of vaccine is one of the important issues, which need to be taken into account during 
development process. In this study, vaccine candidates were composed of peptide antigen and 
polyacrylate polymer. Despite, polyacrylate is not biodegradable, it has well-established safety 
profile. Peptide-polymer conjugates were self-assembled to form particles, and thus molecules were 
brought together by hydrophobic interaction and not covalent bonds. It is expected that such particle 
will disassemble with time and will be eliminated from the body, as single conjugates have 
molecular weight below 30 kDa. Molecules of such weight are easily cleared by kidney [1, 2]. 
Furthermore, the quantity of polymer accumulated in body will be small, as this polymer-peptide 
based vaccine only requires a single-shot vaccination. The conjugation between polymer and 
peptide antigen was performed with the help of copper. Therefore, some amount of copper might be 
present in final product. Only trace copper (below 100ppb) was remaining after purification of each 
vaccine candidates. As the recommended health standard level of copper is below 15 ppm, the 
vaccine candidates meet safety requirement (this has been mentioned in Chapter 5 article). In 
general, copper is an essential trace metal that is required for the activity of several important 
cellular enzymes and consider as essential trace element for human body. Excess of copper is easily 
removed from the body by cellular copper efflux. Copper toxicity is often caused by dysfunction of 
efflux system rather than excessive intake of copper [3]. Overall, the presence of polyacylate and 
trace of copper in the vaccine candidates should not raise any health consideration. 
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6.1 Conclusions 
Although anti-cancer agents that are widely used for cancer chemotherapy are clinically effective in 
cancer treatment, many patients still suffer from its significant drawbacks such as extensive 
undesired adverse effects, dose-limiting toxicity and frequent ineffectiveness, and still may 
succumb to the disease. Therapeutic vaccination is one of the most promising alternative methods 
of anti-cancer therapy. A preventive vaccine against the HPV infection that causes cervical cancer 
has been developed already; however, there is no therapeutic vaccine against this cancer. The 
strategy presented in this thesis represents a novel approach towards the development of a safe and 
potent therapeutic peptide-based vaccine against cervical cancer. To overcome the poor 
immunogenicity of peptide-based vaccines without the use of a toxic adjuvant for vaccine 
formulation, a polymer-based vaccine delivery system was designed and developed. This system 
was based on polyacrylate polymer conjugated to synthetic peptides via CuAAC “click” reaction. 
The delivery platform described herein was able to support induction of cellular immunity against 
short peptide epitopes to target HPV infections. 
 
The E7 oncoprotein is one of the most favorable targets for HPV vaccine development as it is 
necessary for the induction and maintenance of HPV-related disease. The well-known 8Q epitope 
derived from HPV-16 E7 protein was selected as a promising epitope candidate as it contains both 
CTL and T helper cell epitopes. During preparation of the peptide epitope, a so-called “difficult” 
sequence within the 8Q epitope was found to be composed of β-branched amino acids (the IVT 
tripeptide). The presence of this sequence predisposed the peptide to aggregate on the resin via β-
sheet formation that inhibited completion of Fmoc group deprotection, causing a significant amount 
of amino acid deletion products during SPPS. The synthesis of peptide epitopes was successfully 
improved by a change to the standard SPPS and application of the O-N acyl migration-based 
(isopeptide) method. For the design of new peptide epitopes derived from 8Q, the cysteine moieties 
were altered to avoid uncontrolled aggregation of 8Q that resulted from disulfide bridge formation. 
 
In tumor treatment experiments, only the conjugate containing 8Qmin epitope was able to reduce and 
eradicate E7-positive TC-1 tumors in mice after a single-dose vaccination, without the addition of 
an external adjuvant. Other chemically modified 8Q epitopes showed very poor efficacy in 
eradication of tumor in mice. It was suggested that alteration of the 8Q sequence disrupted antigen 
processing and consequently decreased the CTL response. In contrast, 8Qmin possessed shortened 
but not a modified sequence of 8Q. It was also found that the polymer itself did not show any 
adjuvanting properties but, once incorporated into the conjugate and formulated into particles, it 
was able to stimulate the desired immune responses. Further structure-activity assessments 
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demonstrated the lead vaccine conjugate, 8Qmin conjugated to a dendritic polymer, induced more 
potent anti-tumor activity than a formulation that incorporated a classical commercial adjuvant and 
other types of polymers. However, the difference of inducing immune response in the linear and 
dendritic polymer delivery systems was not statistically significant. With regard to our observation, 
less sophisticated analogues of the lead compound that possessed a linear polymer moiety may be 
used as a simpler and cheaper alternative for further vaccine development. 
 
The immunological properties of the polymer-peptide conjugates were also investigated. It was 
shown that the conjugates were efficiently taken up by APCs (including DCs and macrophages), 
stimulated CD8+ and CD4+ T cell activation, and that CD8+ CTLs played a major role in the anti-
tumor immunity induced by the conjugates. Thus, the conjugate showed a potent capacity to 
stimulate cellular immune responses. It was also proven that the conjugates did not cause hemolysis 
even at high concentrations.  
 
Overall, in the current studies of therapeutic peptide vaccine development, this polymer-based 
delivery system has the capacity to overcome the low immunogenicity of peptide antigens. The self-
adjuvanting properties of self-assembled particles could eliminate the requirement of using a toxic 
adjuvant for vaccine formulation. The self-assembled conjugates may serve as a carrier of choice 
for the design of other peptide-based vaccines that induce adequate cellular immunity against any 
targeted disease. The relatively low cost of the construct’s production, its well defined chemical 
structure, its one entity strategy (or at least minimization of vaccine components) and its safety 
profile have made these polymer-peptide conjugates more advantageous than other anti-cancer 
vaccine candidates. 
 
6.2 Future prospects 
Further investigations on this polymer-based construct are required to fully optimize the self-
adjuvanting platform for peptide-based vaccine delivery. Incorporation of multiple diverse epitopes 
into one conjugate should be evaluated. As the 8Q epitope is a fragment of the E7 oncoprotein, 
additional inclusion of an epitope from the E6 oncoprotein into the current vaccine candidates may 
improve its effectiveness, as both oncogenic proteins are required to maintain HPV-associated 
tumor cell growth. In addition, considering the heterogeneity of the human immune response 
against any one given antigenic epitope, and the common antigenic escape of infectious agents or 
tumors, means incorporation of more than one epitope is clearly beneficial.  
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The polymer-peptide conjugates presented here were able to generate efficient cellular immune 
responses after a single-dose immunization. It would be particularly beneficial to determine an 
optimal vaccine dose. Further investigation of whether therapeutic efficacy will be enhanced by a 
booster regimen is also desirable. 
 
This thesis investigated some immunological properties of the current vaccine candidates and 
provided important information on APC uptake, T cell activation and the subset of lymphocytes that 
contribute most to the anti-tumor immunity upon administration of the conjugates. A better 
understanding of the immunological mechanisms of induction of immune responses by this delivery 
system could help future system improvements and its application for treatment of other than cancer 
disease. Further in-depth immunological characterization may include DC maturation, interferon 
gamma or other cytokine production, and recognition of conjugates by pattern-recognition receptors 
such as Toll-like receptors.  
 
Another major future study may involve investigation of the conjugates’ stability under different 
conditions and their shelf-life. Time-dependent formation of higher aggregates or precipitation of 
the constructs from aqueous solutions needs to be assessed to optimize storage conditions. 
Investigations concerning the following properties may be undertaken to determine: (i) whether 
dried constructs can be re-suspended in aqueous solution to form particles with the desired 
size/morphology; (ii) whether particle solutions can be frozen and remain viable; (iii) whether 
additives are necessary to stabilize formulations; (iv) definition of the optimal storage conditions of 
particle constructs; and (v) whether constructs in large scale can be produced for manufacturing. In 
addition, detailed animal toxicity studies should be performed to establish a comprehensive safety 
profile for the vaccine candidates presented here. 
 
One of the major findings of this research work was the development of a safe and effective 
therapeutic peptide-based vaccine against cancer. It would also be interesting to extend this strategy 
of therapeutic vaccine development to target other common human diseases. 
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